Package Rates

BARIATRIC SURGERY CARDIOLOGY CARDIOTHORACIC SURGERIES DERMATOLOGY Diagnostic center E N T Emergency Room Packages (Care requiring less than 12 hrs stay)
ENDOCRINE SURGERY ENDOCRINOLOGY FOLLOW UP PROCEDURE GASTROENTEROLOGY GENERAL MEDICINE GENERAL SURGERY GENITOURINARY SURGERY
GYNAECOLOGY OBSTETRIC SURGERY HEMATOLOGY HEPATOLOGY INFECTIOUS DISEASES - GENERAL MEDICINE INTERVENTIONAL CARDIOLOGY INTERVENTIONAL RADIOLOGY MEDICAL ONCOLOGY
NEONATOLOGY NEPHROLOGY NEUROLOGY NEUROSURGERY OFMS OPHTHALMOLOGY SURGERIES ORTHOPEDIC TRAUMA
PAEDIATRIC INTENSIVE CARE PAEDIATRIC SURGERIES PAEDIATRICS PLASTIC SURGERY PMR PSYCHIATRY PULMONLOGY
RADIATION ONCOLOGY RHEUMATOLOGY SPINE STEMI SURGICAL GASTRO ENTEROLOGY SURGICAL ONCOLOGY THORACIC MEDICINE
VASCULAR SURGERIES

Package NameCategoryA1A2A3A4 A5A6S1S2
CM0100 : BREAST CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-a : BREAST CANCER - combined regimen AC & T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-a-I : BREAST CANCER - Dose Dense AC (Adriamycin/Cyclophosphamide) ; (Day 1: Doxorubicin 60mg/m2 IV, Cyclophosphamide 600mg/m2 IV) ; Repeat cycle - every 14 days for 4 cycles; Followed by Paclitaxel for 4 cycles MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
CM0100-a-II : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 14 days for 4 cycles MEDICAL ONCOLOGY 7000 7000 7000 7000 7000 7000 7000 7000
CM0100-b : BREAST CANCER - TC (Doectaxel & Cyclophosphamide) ; Day 1: Docetaxel 75mg/m2 IV, Cyclophosphamide 600mg/m2 IV ; Repeat cycle - every 21 days for 4 cycles MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
CM0100-c : BREAST CANCER - CMF (Cyclophosphamide/Methotrexate/Fluorouracil) - (includes day 1 & day 8) ; Days 1-14: Cyclophosphamide 100mg/m2 orally ; Days 1 and 8: Methotrexate 40mg/m2 IV ; Days 1 and 8: 5-fluorouracil 600mg/m2 IV. ; Repeat cycle - every 28 days for 6 cycles MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
CM0100-d : BREAST CANCER - EC (Epirubicin/Cyclophosphamide) ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 830mg/m2 IV. ; Repeat cycle - every 21 days for 8 cycles MEDICAL ONCOLOGY 5100 5100 5100 5100 5100 5100 5100 5100
CM0100-e : BREAST CANCER - FEC + T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-e-I : BREAST CANCER - FEC/CEF followed by T (Fluorouracil/Epirubicin/Cyclophosphamide) - followed by Docetaxel or followed by weekly Paclitaxel) ; Day 1: 5-fluorouracil 500mg/m2 IV ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle every 21 days for 3 cycles MEDICAL ONCOLOGY 5100 5100 5100 5100 5100 5100 5100 5100
CM0100-e-II : BREAST CANCER - Docetaxel - (Preceeded by FEC/CEF ) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle - every 21 days for 3 cycles MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
CM0100-e-III : BREAST CANCER - Paclitaxel - weekly - (Preceeded by FEC/CEF ) ; Paclitaxel 100mg/m2 IV ; Repeat cycle - once weekly for 8 weeks MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
CM0100-f : BREAST CANCER - FAC + T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-f-I : BREAST CANCER - FAC followed by T (Fluorouracil/Adriamycin/Cyclophosphamide) - followed by weekly Paclitaxel ; 5-fluorouracil 500mg/m2 IV Days 1 and 8 OR 1 and 4: ; Day 1: Doxorubicin 50mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle - every 21 days for 6 cycles MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
CM0100-f-II : BREAST CANCER - Paclitaxel - weekly - Preceeded by FAC ; Paclitaxel 80mg/m2 IV ; Repeat Cycle weekly for 12 weeks. MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
CM0100-g : BREAST CANCER - TAC (Docetaxel/Adriamycin/Cyclophosphamide) ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
CM0100-h : BREAST CANCER - AC followed by T + Trastuzumab MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-h-I : BREAST CANCER - AC - followed by Paclitaxel + Trastuzumab +/- Pertuzumab ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle - every 21 days for 4 cycle MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
CM0100-h-II : BREAST CANCER - Paclitaxel (Preceeded by AC) ; (To be choosen along with Trastuzumab package - CM0100-h-III or CM0100-h-IV or CM0100-h-V) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
CM0100-h-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with Paclitaxel Cycle 1, 4, 7, 10 and standalone for the upto 1 year every 21 days) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-h-IV : BREAST CANCER - Trastuzumab 4mg (Followed by Trastuzumab 2mg subsequent weeks) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-h-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 2mg/kg IV weekly Till one year from Day 1 of AC. ; (to be approved with Paclitaxel Cycles 2 - 12 and standalone for the upto 1 year every week) MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
CM0100-i : BREAST CANCER - TCH MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-i-I : BREAST CANCER - TC (Docetaxel/Carboplatin) ; (To be choosen along with Trastuzumab package - CM0100-i-II or CM0100-i-III or CM0100-i-IV) ; Day 1: Docetaxel 75mg/m2 IV; Carboplatin AUC 6mg per min/mL IV. ; every 21 days for 6 cycles MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
CM0100-i-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with TC package CM0100-i-I) ; Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with TC Cycle 1 to 6 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 18 weeks as standalone for the upto 1 year every 21 days) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-i-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with TC package CM0100-i-I) ; Day 1: Trastuzumab 4mg/kg IV ; (First dose - only to be approved with TC Cycle 1. Subsequent cycles - 2mg package only) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-i-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses - Weekly) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 17 weeeks may overlap with TC Cycles 2 - 6. To be followed by Trastuzumab (6mg) package upto 1 year MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
CM0100-j : BREAST CANCER - AC followed by Docetaxel + Trastuzumab MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-j-I : BREAST CANCER - AC - followed by Docetaxel + Trastuzumab ; Day 1: Doxorubicin 60mg/m2 IV; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
CM0100-j-II : BREAST CANCER - Docetaxel (preceeded by AC) + Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-j-III or CM0100-j-IV or CM0100-j-V) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
CM0100-j-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel package CM0100-j-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat every 21 days till 1 year ; (to be approved with Docetaxel Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) or from 13 th week after completion of 12 weeks of weekly Trastuzumab - upto 1 year every 21 days) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-j-IV : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel package CM0100-j-II) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel Cycle 1. Subsequent cycles - 2mg package only) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-j-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
CM0100-k : BREAST CANCER - Docetaxel + Cyclophosphamide + Trastuzumab MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-k-I : BREAST CANCER - Docetaxel + Cyclophosphamide - with Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-k-II or CM0100-k-III or CM0100-k-IV) ; Day 1: Docetaxel 75mg/m2 IV; Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
CM0100-k-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Day 1: Trastuzumab 6mg/kg IV ; (to be approved with Docetaxel + Cyclophosphamide Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-k-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel + Cyclophosphamide Cycle 1. Subsequent cycles - 2mg package only) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-k-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel + Cyclophosphamide Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
CM0100-L : BREAST CANCER - Paclitaxel + Trastuzumab MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-L-I : BREAST CANCER - Paclitaxel - (with Trastuzumab) ; (To be choosen along with Trastuzumab package - CM0100-L-III or CM0100-L-IV) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
CM0100-L-II : BREAST CANCER - Trastuzumab (6mg) ; trastuzumab 6mg/kg IV ; Repeat every 21 days ; (to be approved after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-L-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
CM0100-L-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Day 1: Trastuzumab 2mg/kg IV weekly ; (to be approved with Paclitaxel Cycles 2 - 12. May be approved as standalone for the upto 1 year every week or Trastuzumab 6mg Package may be used once every 21 days upto 1 year) MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
CM0100-M : BREAST CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0101 : BLADDER CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0101-a-I : BLADDER CANCER - DDMVAC ; Day 1: Methotrexate 30mg/m2 IV; Day 2: Vinblastine 3mg/m2 IV, doxorubicin 30mg/m2 IV, cisplatin 70mg/m2 IV; ; Repeat every 2 weeks for 3-4 cycles MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
CM0101-a-II : BLADDER CANCER - Gemcitabine + cisplatin ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV; Day 2: Cisplatin 70mg/m2. ; Repeat every 4 weeks for 4 cycles. MEDICAL ONCOLOGY 6400 6400 6400 6400 6400 6400 6400 6400
CM0101-a-III : BLADDER CANCER - Cisplatin + methotrexate + vinblastine (CMV) ; Day 1: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV; Day 2: Cisplatin 100mg/m2 IV, leucovorin 15mg oral or IV every 6 hours for 4 doses; Day 8: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV Day 9: Leucovorin 15mg oral every 6 hours for 4 doses ; Repeat every 3 weeks for 3 cycles. MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
CM0101-b : BLADDER CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0102 : LUNG CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0102-i : LUNG CANCER - Mesothelioma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0102-i-a : LUNG CANCER - Mesothelioma - Pemetrexed + cisplatin ; Day 1: Pemetrexed 500mg/m2 IV, cisplatin 75mg/m2 ; Repeat every 21 days up to 12 cycles. MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
CM0102-i-b : LUNG CANCER - Mesothelioma - Pemetrexed + carboplatin ; Day 1: Pemetrexed 500mg/m2 IV, carboplatin AUC 5mg/min/mL IV. ; Repeat every 21 days for a max of 9 cycles. MEDICAL ONCOLOGY 16500 16500 16500 16500 16500 16500 16500 16500
CM0102-i-c : LUNG CANCER - Mesothelioma - Cisplatin & Gemcitabine ; Day 1: Cisplatin 80-100mg/m2 IV ; Days 1, 8, and 15: Gemcitabine 1000-1250mg/m2 IV ; Repeat every 21 - 28 days for 6 cycles. MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
CM0102-i-d : LUNG CANCER - Mesothelioma - Vinorelbine ; Vinorelbine 25-30mg/m2 (max 60mg) IV ; Repeat every week for 12 weeks. MEDICAL ONCOLOGY 9000 9000 9000 9000 9000 9000 9000 9000
CM0102-i-e : LUNG CANCER - Mesothelioma - Pemetrexed ; Day 1: Pemetrexed 500mg/m2 IV. ; Repeat every 21 days for 4 cycles (If First line) or Repeat every 21 days for 8 cycles (If Second line) MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
CM0102-i-f : LUNG CANCER - Mesothelioma - Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1250mg/m2 IV. ; Repeat every 28 days for a max of 10 cycles. MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
CM0102-i-g : LUNG CANCER - Mesothelioma - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0102-ii : LUNG CANCER - NSCLC MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0102-ii-a : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (i) ; Days 1 and 8: Cisplatin 50mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 25mg/m2 IV ; (or) ; Day 1: Cisplatin 100mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 30mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. MEDICAL ONCOLOGY 33600 33600 33600 33600 33600 33600 33600 33600
CM0102-ii-b : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (ii) ; Day 1: Cisplatin 75-80mg/m2 ; Days 1 and 8: Vinorelbine 25-30mg/m2. ; Repeat every 3 weeks for 4 cycles MEDICAL ONCOLOGY 17900 17900 17900 17900 17900 17900 17900 17900
CM0102-ii-c : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 100mg/m2 IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles MEDICAL ONCOLOGY 4900 4900 4900 4900 4900 4900 4900 4900
CM0102-ii-d : LUNG CANCER - NSCLC - Cisplatin & Docetaxel ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
CM0102-ii-e : LUNG CANCER - NSCLC - Cisplatin & Gemcitabine ; Day 1: Cisplatin 75mg/m2 IV ; Days 1 and 8: Gemcitabine 1,250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
CM0102-ii-f : LUNG CANCER - NSCLC - Pemetrexed + cisplatin (for Non Squamous Cell CA) ; Day 1: Cisplatin 75mg/m2 IV, pemetrexed 500mg/m2 IV. ; Repeat every - 21 days for 4 cycles. MEDICAL ONCOLOGY 14500 14500 14500 14500 14500 14500 14500 14500
CM0102-ii-g : LUNG CANCER - NSCLC - Paclitaxel/Carboplatin ; Day 1: Paclitaxel 200mg/m2 IV, carboplatin AUC 6mg per min/mL IV. ; Repeat cycle every 3 weeks for 4 cycles. MEDICAL ONCOLOGY 8100 8100 8100 8100 8100 8100 8100 8100
CM0102-ii-h : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Days 1, 8, 29 and 36: Cisplatin 50mg/m2 IV ; Days 1-5 and 29-33: Etoposide 50mg/m2 IV ; Concurrent thoracic radiotherapy 1.8Gy/day for 5 days/week (total dose, 61Gy). MEDICAL ONCOLOGY 8500 8500 8500 8500 8500 8500 8500 8500
CM0102-ii-i : LUNG CANCER - NSCLC - Cisplatin & Vinblastine ; Days 1 and 29: Cisplatin 100mg/m2 IV ; Days 1, 8, 15, 22 and 29: Vinblastine 5mg/m2 IV ; concurrent thoracic radiotherapy (total dose, 60Gy). MEDICAL ONCOLOGY 8200 8200 8200 8200 8200 8200 8200 8200
CM0102-ii-j : LUNG CANCER - NSCLC - Carboplatin + Pemetrexed ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 4 cycles. MEDICAL ONCOLOGY 16500 16500 16500 16500 16500 16500 16500 16500
CM0102-ii-k : LUNG CANCER - NSCLC - Cisplatin + Pemetrexed ; Day 1: Cisplatin 75 mg/m2 IV. ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 3 cycles. MEDICAL ONCOLOGY 14900 14900 14900 14900 14900 14900 14900 14900
CM0102-ii-l : LUNG CANCER - NSCLC - Paclitaxel + Carboplatin ; Paclitaxel 45mg/m2 IV + carboplatin AUC 2mg per min/mL IV ; with concurrent thoracic radiotherapy (total dose, 60Gy) ; Repeat weekly for 6 weeks MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
CM0102-ii-m : LUNG CANCER - NSCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0102-iii : LUNG CANCER - SCLC MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0102-iii-a : LUNG CANCER - SCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 60mg/m2 IV, Days 1-3: Etoposide 120mg/m2 IV. ; Repeat cycle every 3 weeks for at least 4 cycles. ;(OR) ; Day 1: Cisplatin 80mg/m2 IV, Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4-6 cycles. MEDICAL ONCOLOGY 4900 4900 4900 4900 4900 4900 4900 4900
CM0102-iii-b : LUNG CANCER - SCLC - Carboplatin & Etoposide ; Day 1: Carboplatin AUC 5-6mg per min/mL IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 21 days or 28 days for 4 - 6 cycles MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0102-iii-c : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
CM0102-iii-d : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1 and 8: Cisplatin 30mg/m2 IV, irinotecan 65mg/m2 IV. ; Repeat cycle every 3 weeks for 4-6 cycles. MEDICAL ONCOLOGY 5700 5700 5700 5700 5700 5700 5700 5700
CM0102-iii-e : LUNG CANCER - SCLC - Carboplatin & Irinotecan ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 50mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles MEDICAL ONCOLOGY 7700 7700 7700 7700 7700 7700 7700 7700
CM0102-iii-f : LUNG CANCER - SCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0103-i : ESOPHAGEAL CANCER - Neo Adjuvant MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0103-i-a : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV + carboplatin AUC 2mg/min/mL IV. ; Repeat weekly for 5 weeks MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
CM0103-i-b : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV. MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
CM0103-i-c : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5 and Days 22-26: 5-FU 800 mg/m2 IV ; Repeat every 21 days for 2 cycles MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
CM0103-i-d : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil + Oxaliplatin + Leucovorin ; Day 1: Oxaliplatin 85mg/m2, leucovorin 200mg/m2 and 5-FU 400mg/m2 bolus, with 1,600mg/m2 infusion; ; Repeat every 14 days for 6 cycles MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
CM0103-i-e : ESOPHAGEAL CANCER - Neo Adjuvant - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
CM0103-i-f : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV MEDICAL ONCOLOGY 25800 25800 25800 25800 25800 25800 25800 25800
CM0103-i-g : ESOPHAGEAL CANCER - Neo Adjuvant - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks. MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
CM0103-i-h : ESOPHAGEAL CANCER - Neo Adjuvant - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV, cisplatin 30mg/m2 IV. MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
CM0103-i-i : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV infusion. ; Repeat cycle weekly for 5 weeks. MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
CM0103-i-j : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. MEDICAL ONCOLOGY 12200 12200 12200 12200 12200 12200 12200 12200
CM0103-i-k : ESOPHAGEAL CANCER - Neo Adjuvant - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0103-ii : ESOPHAGEAL CANCER - Peri-Operative MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0103-ii-a : ESOPHAGEAL CANCER - Peri-Operative - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV continuous infusion once daily; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively MEDICAL ONCOLOGY 16700 16700 16700 16700 16700 16700 16700 16700
CM0103-ii-b : ESOPHAGEAL CANCER - Peri-Operative - EOF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
CM0103-ii-c : ESOPHAGEAL CANCER - Peri-Operative - EOC (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. MEDICAL ONCOLOGY 7800 7800 7800 7800 7800 7800 7800 7800
CM0103-ii-d : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV ; Repeat cycle every 28 days for 2-4 cycles MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
CM0103-ii-e : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cyclesCycled every 21 days for 2 cycles MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
CM0103-ii-f : ESOPHAGEAL CANCER - Peri-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0103-iii : ESOPHAGEAL CANCER - Post-Operative MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0103-iii-a : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (i) ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV, followed by 4 weeks break and CCRT ; RT Days 1-4 and 23-25: 5-FU 400mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV. MEDICAL ONCOLOGY 25400 25400 25400 25400 25400 25400 25400 25400
CM0103-iii-b : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 200mg/m2 IV, 5-FU 400mg/m2 IV push and 5-FU 600mg/m2 infusion MEDICAL ONCOLOGY 9000 9000 9000 9000 9000 9000 9000 9000
CM0103-iii-c : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily; ; Repeat every 28 days; 1 cycle before and 2 cycles after chemoradiation MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
CM0103-iii-d : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily, ; once weekly for 5 weeks. MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
CM0103-iii-e : ESOPHAGEAL CANCER - Post-Operative - FluorouracilDays 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV continuous infusion over 24 hours daily, ; once weekly for 5 weeks.once weekly for 5 weeks. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0103-iii-f : ESOPHAGEAL CANCER - Post-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0103-iv : ESOPHAGEAL CANCER - Definitive MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0103-iv-a : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
CM0103-iv-b : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cycles MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
CM0103-iv-c : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day continuous IV infusion. MEDICAL ONCOLOGY 25800 25800 25800 25800 25800 25800 25800 25800
CM0103-iv-d : ESOPHAGEAL CANCER - Definitive - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
CM0103-iv-e : ESOPHAGEAL CANCER - Definitive - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
CM0103-iv-f : ESOPHAGEAL CANCER - Definitive - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV and carboplatin 2mg/min/mL IV ; Repeat weekly for 5 weeks. MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
CM0103-iv-g : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (i) ; Days 1 and 22: Docetaxel 60mg/m2 IV ; Days 1 and 22: Cisplatin 60-80mg/m2 IV given for 1 cycle MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
CM0103-iv-h : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (ii) ; Day 1: Docetaxel 20-30mg/m2 IV ; Day 1: Cisplatin 20-30mg/m2 IV ; Repeat weekly for 5 weeks MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
CM0103-iv-i : ESOPHAGEAL CANCER - Definitive - Cisplatin with Paclitaxel ; Days 1, 8, 15, and 22: Paclitaxel 60mg/m2 IV ; Day 1: Cisplatin 75mg/m2 IV given for 1 cycle. MEDICAL ONCOLOGY 13100 13100 13100 13100 13100 13100 13100 13100
CM0103-iv-j : ESOPHAGEAL CANCER - Definitive - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV ; Days 1, 8, 22, and 29: Cisplatin 30mg/m2 IV. MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
CM0103-iv-k : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV ; Repeat cycle weekly for 5 weeks. MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
CM0103-iv-l : ESOPHAGEAL CANCER - Definitive - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 PO twice daily. ; Repeat cycle weekly for 5 weeks. MEDICAL ONCOLOGY 12200 12200 12200 12200 12200 12200 12200 12200
CM0103-iv-m : ESOPHAGEAL CANCER - Definitive - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0104 : GASTRIC CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0104-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0104-i-a : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV, carboplatin AUC 2mg/min/mL IV. ; Repeat cycle weekly for 5 weeks. MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
CM0104-i-b : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1000mg/m2/day IV MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
CM0104-i-c : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV once daily, 5-FU 800mg/m2/day IV ; Repeat cycle every 21 days for 2 cycles. MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
CM0104-i-d : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (i)Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV. MEDICAL ONCOLOGY 25800 25800 25800 25800 25800 25800 25800 25800
CM0104-i-e : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (ii)Day 1: Oxaliplatin 85mg/m2 and leucovorin 400mg/m2 followed by 5-FU 400mg/m2 bolus, then 800mg/m2 24-hour continuous infusion over days 1 and 2; the first 3 cycles were delivered during radiotherapy (RT), the other 3 after RT; 6 bimonthly (14 days) cycles. MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
CM0104-i-f : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
CM0104-i-g : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
CM0104-i-h : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45-50mg/m2 IV weekly ; Days 1-5: 5-FU 300mg/m2 IV ; Repeat cycle weekly for 5 weeks MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
CM0104-i-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
CM0104-i-j : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0104-ii : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0104-ii-a : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV, cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2/day IV ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively MEDICAL ONCOLOGY 16700 16700 16700 16700 16700 16700 16700 16700
CM0104-ii-b : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - EOF (Epirubicin/ oxaliplatin /Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
CM0104-ii-c : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - epirubicin + cisplatin + capecitabine ; Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
CM0104-ii-d : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF modification (epirubicin + oxaliplatin + capecitabine) ; Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperativelyRepeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively MEDICAL ONCOLOGY 7800 7800 7800 7800 7800 7800 7800 7800
CM0104-ii-e : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Fluorouracil & Cisplatin ; Day 1: Cisplatin 75-80mg/m2 IV ; Days 1-5: 5-FU 800mg/m2 IV ; Repeat cycle every 28 days for 2-3 cycles preoperatively and 3-4 cycles postoperatively for a total of 6 cycles. MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
CM0104-ii-f : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0104-iii : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0104-iii-a : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (i) ; Cycles 1, 3, and 4 (before and after radiation) Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2/day IV ; Repeat cycle every 28 days. ; Cycle 2 (with radiation) Days 1-4 and 31-33: Leucovorin 20mg/m2 IVP ; Days 1-4: 5-FU 400mg/m2/day IVP. ; Repeat cycle every 35 days MEDICAL ONCOLOGY 25400 25400 25400 25400 25400 25400 25400 25400
CM0104-iii-b : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 400mg/m2 IV, 5-FU 400mg/m2 IV and 5-FU 1200mg/m2 infusion; ; 1 cycle before and 2 cycles after chemoradiation. ; Repeat cycle every 28 daysRepeat cycle every 28 days MEDICAL ONCOLOGY 14900 14900 14900 14900 14900 14900 14900 14900
CM0104-iii-c : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily. ; Repeat cycle every 28 days; 1 cycle before and 2 cycles after chemoradiation. MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
CM0104-iii-d : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily; weekly for 5 weeks. MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
CM0104-iii-e : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil ; Days 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV; ; weekly for 5 weeks. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0104-iii-f : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Cisplatin + capecitabine ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 6 cycles. MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
CM0104-iii-h : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Oxaliplatin + capecitabine ; Day 1: Oxaliplatin 130mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 8 cycles.Repeat cycle every 21 days for 8 cycles. MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
CM0104-iii-i : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0105-i : COLORECTAL CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0105-i-a : COLORECTAL CARCINOMA - FOLFOX (Stage - III) - (Oxaliplatin, Leucovorin, 5-FU) ; Day 1: Oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV , 5-FU 400mg/m2 IV, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) over 46-48-hour continuous infusion. ; Repeat cycle every 2 weeks- upto 12 cycles MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
CM0105-i-b : COLORECTAL CARCINOMA - CAPEOX (Stage - III) (Oxaliplatin, Capecitabine) ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Days 1-14: Capecitabine 1,000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 6 months MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0105-i-c : COLORECTAL CARCINOMA - FLOX (Stage - III) (5-FU, leucovorin, oxaliplatin) ; 5-FU 500mg/m2 IV bolus weekly x 6, leucovorin 500mg/m2 IV weekly x 6, each ; oxaliplatin 85mg/m2 IV on weeks 1, 3, and 5 ; 8-week cycle x 3 cycles ; MEDICAL ONCOLOGY 30000 30000 30000 30000 30000 30000 30000 30000
CM0105-i-d : COLORECTAL CARCINOMA - Capecitabine ; Capecitabine 1,250mg/m2 - BD / TDS D 1-14 ; every 3 weeks * 24 weeks MEDICAL ONCOLOGY 4300 4300 4300 4300 4300 4300 4300 4300
CM0105-i-e : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (i) ; Leucovorin 500mg/m2 weekly x 6 weeks, ; 5-FU 500mg/m2 weekly x 6 weeks. ; Repeat cycle every 8 weeks for 4 cycles. MEDICAL ONCOLOGY 23700 23700 23700 23700 23700 23700 23700 23700
CM0105-i-f : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (ii)Simplified biweekly infusion. ; Leucovorin 400mg/m2 IV, 5-FU bolus 400mg/m2 and then 1,200mg/m2/day x 2 days (total 2,400mg/m2 over 46-48 hours) ; Repeat cycle every 2 weeks for 6 cycles. MEDICAL ONCOLOGY 5200 5200 5200 5200 5200 5200 5200 5200
CM0105-i-g : COLORECTAL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0105-ii : COLORECTAL CARCINOMA - Concurrent MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0105-ii-a : COLORECTAL CARCINOMA - Concurrent - 5FU - with XRT ; Days 1-5 OR 1-7: 5-FU 225mg/m2 IV ; with External beam radiotherapy MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
CM0105-ii-b : COLORECTAL CARCINOMA - Concurrent - Fluorouracil + Leucovorin - with XRT ; Days 1-4: 5-FU 400mg/m2 IV + leucovorin 20mg/m2 IV. ; Repeat cycle during weeks 1 and 5 of XRT. MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
CM0105-ii-c : COLORECTAL CARCINOMA - Concurrent - Capecitabine - with XRT ; Capecitabine Tablet 825mg / m2 twice daily on Days 1-5 ; Repeat cycle weekly for 5 weeks. MEDICAL ONCOLOGY 1300 1300 1300 1300 1300 1300 1300 1300
CM0105-ii-d : COLORECTAL CARCINOMA - Concurrent - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0106-106 : OSTEOSARCOMA/ BONE TUMORS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0106-i-a : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Cisplatin + doxorubicin ; Days 1-3: Doxorubicin 25mg/m2/day IV, ; Day 1: Cisplatin 100mg/m2 IV ; Repeat cycle every 3 weeks for 6 cycles MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
CM0106-i-b-1 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - PRE OPERATIVE ; Days 1 and 28: Methotrexate 8g/m2 IV ; Days 7-9 and 34-36: Cisplatin 120mg/m2 by infusion for 72 hours. ; Days 9 and 36: Doxorubicin 60mg/m2 IV MEDICAL ONCOLOGY 24200 24200 24200 24200 24200 24200 24200 24200
CM0106-i-b-2 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS < 90% ; Days 1, 48, 96, and 144: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 69, and 117: Methotrexate 8g/m2 IV ; Days 27, 75, and 123: Cisplatin 120mg/m2 by infusion for 72 hours. MEDICAL ONCOLOGY 40100 40100 40100 40100 40100 40100 40100 40100
CM0106-i-b-3 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS > 90%Postoperative Chemotherapy (Necrosis <90%) ; Days 1, 69, 138, and 207: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 90, and 159: Ifosfamide 2g/m2/day IV for 5 consecutive days + mesna ; Days 42, 111, and 180: Methotrexate 8g/m2 IV ; Days 48, 117, and 186: Etoposide 120mg/m2/day for 3 days. MEDICAL ONCOLOGY 59100 59100 59100 59100 59100 59100 59100 59100
CM0106-i-c : Doxorubicin + cisplatin + ifosfamide + high-dose methotrexate (surgery to be done also) MEDICAL ONCOLOGY 111505 111505 111505 111505 111505 111505 111505 111505
CM0106-i-d : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Ifosfamide + cisplatin + epirubicin ; Day 1: Epirubicin 90mg/m2 IV, cisplatin 100mg/m2 IV ; Days 2-4: Ifosfamide 2.0g/m2 with mesna ; Repeat cycle every 21 days. (3 cycles preoperatively and 3 cycles postoperatively). MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
CM0106-ii : Other bone tumors - Chordroma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0106-ii-a : Other bone tumors - Chordroma - Imatinib ; Imatinib 800 mg once daily MEDICAL ONCOLOGY 4500 4500 4500 4500 4500 4500 4500 4500
CM0106-ii-b : Other bone tumors - Chordroma - Imatinib + cisplatin ; Imatinib 400mg OD + cisplatin 25mg/m2 weekly. MEDICAL ONCOLOGY 4500 4500 4500 4500 4500 4500 4500 4500
CM0106-ii-c : Other bone tumors - Chordroma - Imatinib + sirolimus ; Imatinib 400mg OD + sirolimus 2mg OD MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
CM0106-ii-d : Other bone tumors - Chordroma - Erlotinib ; Erlotinib 150mg OD MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
CM0106-ii-e : Other bone tumors - Chordroma - Sunitinib ; Sunitinib 37.5mg OD MEDICAL ONCOLOGY 28500 28500 28500 28500 28500 28500 28500 28500
CM0106-iii :Other bone tumors - Giant Cell Tumor of Bone MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0106-iii-a :Other bone tumors - Giant Cell Tumor of Bone - Denosumab ; Denosumab 120mg subcutaneous on Week 1,2 and 3 of a 4 week cycle MEDICAL ONCOLOGY 56000 56000 56000 56000 56000 56000 56000 56000
CM0106-iii-b :Other bone tumors - Giant Cell Tumor of Bone - Interferon alfa ; interferon alfa- 2a thrice weekly MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
CM0106-iii-c :Other bone tumors - Giant Cell Tumor of Bone - Peginterferon ; Peginterferon alfa-2a 1.0mcg/kg SQ injection weekly. MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
CM0106-iv : Other bone tumors - Mesenchymal Chordosarcoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0106-iv-a : VAC and IE cycles MEDICAL ONCOLOGY 6420 6420 6420 6420 6420 6420 6420 6420
CM0106-iv-b : Other bone tumors - Mesenchymal Chordosarcoma VAIA ; Day 1: Vincristine 1.5mg/m2 IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 3 weeks. MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
CM0106-v : Other bone tumors - Mesenchymal Chordosarcoma Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0107 : WILMS TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0107-a : WILMS TUMOR - Vincristine & Actinomycin D ; Dactinomycin 45mcg/kg - week - 0, 3, 6,9,12,15,18 ; Vincristine 1.5 mg/m2 - week - 1,2,3,4,5,6,7,8,9,10,12,15,18 MEDICAL ONCOLOGY 19400 19400 19400 19400 19400 19400 19400 19400
CM0107-b : WILMS TUMOR - Dactinomycin, Vincristine & Adriamycin ; Dactinomycin 1.35 mg /m2 - week - 0, 6, 12, 18,24 ; Adriyamycin 30-45 mg /m2- week - 3, 9, 15, 21 ; Vincristine 2mg max- week - 1,2,3,4,5,6,7,8,9,10,12,15,18,21,24 MEDICAL ONCOLOGY 23200 23200 23200 23200 23200 23200 23200 23200
CM0107-c : WILMS TUMOR - Adriamycin, Cyclophosphamide, Etoposide, Vincristine ; Cyclophosphamide 440mg/m2/day - week 3, 9, 15, 21 for 5 days, week - 6,12,18,24 for 3 days ; Adriyamycin 30-45mg /m2- week -0, 6, 12, 18,24 ; Vincristine 2mg (max)- week - 1,2,4,5,6,7,8,10,11, 12,13,18,24 ; Etoposide 100mg /m2- week - 3,9,15,21 MEDICAL ONCOLOGY 53700 53700 53700 53700 53700 53700 53700 53700
CM0107-d : WILMS TUMOR - Cyclophosphamide, Etoposide, Carboplatin ; Cyclophosphamide 440mg/m2/day - week 6,15,24 *5 days / week ; Carboplatin 500mg/m2 - week - 0,3,9,12,18,21 *2 days / week ; Etoposide 100mg/m2 - week - 0,3,9,12,18,21 *5 days / week MEDICAL ONCOLOGY 84500 84500 84500 84500 84500 84500 84500 84500
CM0107-e : WILMS TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0108 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0108-a : HEPATOBLASTOMA- OPERABLE - PLADO - Cisplatin + Doxorubicin ; cisplatin (PLA) (80mg/m2 / iv), doxorubicin (DO) (30 mg/m2 IV ; Every 21 days for 6 cycles MEDICAL ONCOLOGY 2800 2800 2800 2800 2800 2800 2800 2800
CM0108-b : HEPATOBLASTOMA- OPERABLE - Cisplatin + Vincristine +5FU ; cisplatin (90 mg/m2), vincristine (1.5mg/m2), 5-FU(5-Flurouracil- 600 mg/m2) ; Every 21 days for 6 cycles MEDICAL ONCOLOGY 2400 2400 2400 2400 2400 2400 2400 2400
CM0108-c : HEPATOBLASTOMA- OPERABLE - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0109 : HEPATOCELLULAR CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0109-a : HEPATOCELLULAR CARCINOMA - Sorafenib ; Sorafenib 400 mg PO BID MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
CM0109-b : HEPATOCELLULAR CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0110A : Neuroblastoma ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
CM0110B : Neuroblastoma ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300mg/m2 ; ADRIAMYCIN 60mg/m2 ; VINCRISTINE 1.5mg/m2 MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
CM0110C : Neuroblastoma ALL STAGES - Cisplatin & Etoposide ; Days 1-5 : Cisplatin - 20mg/m2 ; Days 1-5 : Etoposide - 70 mg/m2 MEDICAL ONCOLOGY 4900 4900 4900 4900 4900 4900 4900 4900
CM0110D : Neuroblastoma ALL STAGES - Carboplatin & Etoposide ; Days 1-2 : Carboplatin - 500mg/m2 ; Days 1-5: Etoposide 100mg/m2 MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0110E : Neuroblastoma ALL STAGES - For Stage IV Palliative Chemotherapy only MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0110F : Neuroblastoma ALL STAGES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0111 : RETINOBLASTOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0111-a : RETINOBLASTOMA - Melphalan - Intra-arterial ; Melphalan - 3-7.5mg - Intra-arterial MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
CM0111-b : RETINOBLASTOMA - Carboplatin - Intra-arterial ; Carboplatin 15-30 mg - Intra-arterial MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
CM0111-c : RETINOBLASTOMA - Topotecan - Intra-arterial ; Topotecan 0.15-1.5 mg - Intra-arterial MEDICAL ONCOLOGY 9900 9900 9900 9900 9900 9900 9900 9900
CM0111-d : RETINOBLASTOMA - Methotrexate - Intra-arterial ; Methotrexate 6-12 mg - Intra-arterial MEDICAL ONCOLOGY 8600 8600 8600 8600 8600 8600 8600 8600
CM0111-e : RETINOBLASTOMA - Carboplatin - Peri Ocular ; Carboplatin 20mg/m2 - Peri Ocular MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
CM0111-f : RETINOBLASTOMA - Topotecan - Peri Ocular ; Topotecan 0.09 - 0.27 - Peri Ocular MEDICAL ONCOLOGY 4300 4300 4300 4300 4300 4300 4300 4300
CM0111-g : RETINOBLASTOMA - Melphalan - Intra-vitreal ; Melphalan 20-30 mcg / 0.1cc - Intra-vitreal MEDICAL ONCOLOGY 270 270 270 270 270 270 270 270
CM0111-h : RETINOBLASTOMA - Carboplatin - Intra-vitreal ; Carboplatin 3-6mcg / 0.05cc - Intra-vitreal MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
CM0111-i : RETINOBLASTOMA - Methotrexate - Intra-vitreal ; Methotrexate 400mcg/0.1cc - Intra-vitreal MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
CM0111-j : RETINOBLASTOMA - Carboplatin + Etoposide + Vincristine ; Carboplatin 560mg/m2 ; Etoposide 150mg/m2 ; Vincristine 1.5mg/m2 MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
CM0111-k : RETINOBLASTOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0112 : HISTIOCYTOSIS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0112-a : HISTIOCYTOSIS - Prednisolone and Vinblastine - 1; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
CM0112-b : HISTIOCYTOSIS - Prednisolone and Vinblastine - 2; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
CM0112-c : HISTIOCYTOSIS - Prednisolone and Vinblastine - continuation; Prednisolone and Vinblastine - continuation after either course 1 or both 1 & 2 ; Prednisolone - 5 days a week oral ; Vinblastine -IV ; repeat every 3 weeks till 1 year MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
CM0112-d : HISTIOCYTOSIS - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0113 : RHABDOMYOSARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0113-a : RHABDOMYOSARCOMA - VAC (Vincristine + Dactinomycin + Cyclophosphamide + Mesna ) ; Day -1 - Vincristine 1.5 mg /m2 IV (2 mg max), Doxorubicin 75 mg /m2 IV , cyclophosphamide 1200 mg /m2 IV + mesna ; Repeat at 21 day intervals for 4-6 cycles MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
CM0113-b : RHABDOMYOSARCOMA - IVA (Vincristine + Dactinomycin + Ifosfamide + Mesna ) ; Day 1,2 - Ifosfamide IV 3 g/m2 + mesna ; Day 1 - Vincristine IV 1.5 mg/m2 (max 2 mg), Actinomycin-D IV 1.5 mg/m2 (max 2 mg) ; Repeat at 21 day intervals for 6 cycles MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
CM0113-c : RHABDOMYOSARCOMA - IVAD (Vincristine + Doxorubicin + Ifosfamide + Mesna ) ; Days 1 and 2 - Ifosfamide 3 g/m2 + Mesna, Doxorubicin 30mg/m2 ; Day 1 - vincristine 1.5 mg/m2, Actinomycin-D 1.5 mg/m2 ; Repeat at 21 day intervals for 6 cycles MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
CM0113-d : RHABDOMYOSARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0114 : EWINGS SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0114-i : EWINGS SARCOMA - Induction Treatment I MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0114-i-a : EWINGS SARCOMA - Induction Treatment - VIDE ; Day 1:Vincristine 1.5mg/m2(max 2mg) IV ; Days 1-3:Doxorubicin 20mg/m2 IV, ifosfamide 3g/m2IV, mesna continuous IV, etoposide 150mg/m2 IV ; Repeat cycle every 3 weeks for up to 6 cycles MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
CM0114-i-b : EWINGS SARCOMA - Induction Treatment - VAC/IE ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0114-i-c : EWINGS SARCOMA - Induction Treatment - VAIA - 4 day Regimen ; Day 1:Vincristine 1.5mg/m2IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, then local therapy, followed by 10 additional cycles of VAIA for High risk and ; 10 additional cycles of VAIA or 10 cycles of VACA for standard-risk patients MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
CM0114-i-d : EWINGS SARCOMA - Induction Treatment - VAIA - 24 day Regimen ; Days 1, 8, 15, and 22: Vincristine 1.5mg/m2 IV ; Days 1, 2, 22, 23, 43, and 44 : Ifosfamide 3,000mg/m2 IV + mesna ; Days 1, 2, 43, and 44 : Doxorubicin 30mg/m2 IV ; Days 22, 23, and 24: Dactinomycin 0.5mg/m2 IV ; After completion of one 9-week cycle, local therapy followed by 3 additional cycles. MEDICAL ONCOLOGY 17700 17700 17700 17700 17700 17700 17700 17700
CM0114-ii : EWINGS SARCOMA - Maintenance Treatment MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0114-ii-a : EWINGS SARCOMA - Maintenance Treatment - Etoposide/Ifosfamide ; Days 1-5: Ifosfamide 1,800mg/m2/day IV + mesna ; Days 1-5: Etoposide 100mg/m2/day IV. MEDICAL ONCOLOGY 8200 8200 8200 8200 8200 8200 8200 8200
CM0114-iii : EWINGS SARCOMA - Maintenance Treatment - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0115 : PALLIATIVE CHEMOTHERAPY (Any Regimen)- Maximum Payable MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0116 : CERVICAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0116-a : CERVICAL CANCER - CISPLATIN ; Cisplatin 40mg/m2 IV once weekly for up to 6 cycles MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
CM0116-b : CERVICAL CANCER - Cisplatin & 5FU with RT ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 IV over 96 hours ; Repeat cycle every 3 weeks for 3 MEDICAL ONCOLOGY 9200 9200 9200 9200 9200 9200 9200 9200
CM0116-c : CERVICAL CANCER - Cisplatin & 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
CM0116-d : CERVICAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0117 : VULVAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0117-a : VULVAL CANCER - Cisplatin ; Day 1 : 40 mg/m 2 IV MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
CM0117-b : VULVAL CANCER - Cisplatin + 5FU ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 ; Repeat cycle every 3 weeks - total 3 cycles MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
CM0117-c : VULVAL CANCER - 5-FU + Mitomycin ; 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day continuous IV infusion ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), MEDICAL ONCOLOGY 11400 11400 11400 11400 11400 11400 11400 11400
CM0117-d : VULVAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0118 : VAGINAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0118-a : VAGINAL CANCER - Cisplatin ; Cisplatin 75mg/m2 ; once weekly for up to 6 doses MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
CM0118-b : VAGINAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0119 : OVARIAN CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0119-a : OVARIAN CANCER - Paclitaxel + Cisplatin ; Day 1: Paclitaxel 135mg/m2 continuous IV ; Day 2: Cisplatin 75-100mg/m2 ; Day 8: Paclitaxel 60mg/m2 ; Repeat every 3 weeks for 6 cycles. MEDICAL ONCOLOGY 8800 8800 8800 8800 8800 8800 8800 8800
CM0119-b : OVARIAN CANCER - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 175mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL IV ; Repeat every 3 weeks for 6 cycles MEDICAL ONCOLOGY 7000 7000 7000 7000 7000 7000 7000 7000
CM0119-c : OVARIAN CANCER - Docetaxel + Carboplatin ; Day 1: Docetaxel 60-75mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL ; Repeat every 3 weeks for 6 cycles MEDICAL ONCOLOGY 8700 8700 8700 8700 8700 8700 8700 8700
CM0119-d : OVARIAN CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0120 : ENDOMETRIAL CANCER (Palliative Chemotherapy only) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0121 : OVARY- GERM CELL TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0121-a : OVARY- GERM CELL TUMOR - BEP (Bleomycin + Etoposide + Cisplatin) ; Days 1,8,15 : Bleomycin 30 units/wk IV, Etoposide 100 mg/m 2/day IV ; Days 1-5 : Cisplatin 20 mg/m 2/day IV ; Repeat every 21 days 3-4 cycles MEDICAL ONCOLOGY 10800 10800 10800 10800 10800 10800 10800 10800
CM0121-b : OVARY- GERM CELL TUMOR - EP ( Etoposide + Carboplatin) ; Day 1 : Carboplatin 400 mg/m 2 IV on days 1-3 ; Repeat every 28 days for three cycles MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0121-c : OVARY- GERM CELL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0122 : GESTATIONAL TROPHOBLAST DISEASES MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0122-a : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (5 days regimen) ; Days 1-5: MTX 0.4 mg/kg/day IV or IM for 5 days, not to exceed 25 mg/day ; Repeat cycle every 14 days MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0122-b : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (8-day alternating regimen) ; Days 1, 3, 5, and 7 : MTX 1 mg/kg IM, ; Days 2, 4, 6, and 8 : Folinic acid 15 mg ; Repeat cycle every 14 days MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
CM0122-c : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate + Folinic Acid ; Day 1 : MTX 100 mg/m 2 IVP, then 200 mg/m 2 infusion ; Day 2 : Folinic acid 15 mg IM/PO q12h for 4 doses ; Repeat cycle every 18 days MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
CM0122-d : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate - Weekly ; MTX 30-50 mg/m 2 IM weekly MEDICAL ONCOLOGY 1300 1300 1300 1300 1300 1300 1300 1300
CM0122-e : GESTATIONAL TROPHOBLAST DISEASES - Act-D ; Act-D 10-13 mcg/kg or 0.5-mg flat dose IV qd for 5d ; Repeat cycle every 14 days MEDICAL ONCOLOGY 7800 7800 7800 7800 7800 7800 7800 7800
CM0122-f : GESTATIONAL TROPHOBLAST DISEASES - Actinomycin ; Actinomycin 1.25 mg/m 2 IV ; Repeat every 2 weeks MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
CM0122-g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (complete) ; Day 1 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, MTX - 300 mg/m2 IV ; Day 2 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, Leucovorin - 15 mg PO/IM q12h 4 doses ; Day 8 : Vincristine - 0.8 mg/m2 IV, Cyclophosphamide - 600 mg/m2 IV ; Repeat cycle every 14 days MEDICAL ONCOLOGY 6400 6400 6400 6400 6400 6400 6400 6400
CM0122-h : GESTATIONAL TROPHOBLAST DISEASES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0123 : TESTICULAR CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0123-a : TESTICULAR CANCER - EP ; Days 1-5: Etoposide 100mg/m2, cisplatin 20mg/m2 ; Repeat cycle every 3 weeks for 4 cycles. MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
CM0123-b : TESTICULAR CANCER - BEP ; Days 1-5: Cisplatin 20mg/m2, etoposide 100mg/m2 ; Days 1, 8, and 15 OR Days 2, 9, or 16: Bleomycin 30 units IV ; Repeat cycle every 3 weeks for 3 cycles. MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0123-c : TESTICULAR CANCER - VIP ; Day 1 (before ifosfamide): Mesna 120mg/m2 IV ; Days 1-5: Etoposide 75mg/m2 IV, mesna 1,200mg/m2 IV, ifosfamide 1,200mg/m2 IV + cisplatin 20mg/m2. ; Repeat cycle every 3 weeks for 4 cycles. MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
CM0123-d : TESTICULAR CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0124 : PROSTATE CANCERPROSTATE CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0124-a : PROSTATE CANCER - Docetaxel + prednisone ; Day 1: Docetaxel 75mg/m2 IV, prednisone 5mg orally twice daily. ; once every 3 weeks, Repeat for up to 10 cycles if tolerated MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
CM0124-b : PROSTATE CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0125 : FEBRILE NEUTROPENIA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0125-a : FEBRILE NEUTROPENIA - First-line monotherapy ; Piperacillin-tazobactam 4.5 g ; Cefepime 2 g ; Meropenem 1 g ; Imipenem-cilastatin 500 mg MEDICAL ONCOLOGY 13500 13500 13500 13500 13500 13500 13500 13500
CM0125-b : FEBRILE NEUTROPENIA - Second-line dual therapy ; Piperacillin-tazobactam 4.5 g IV plus an aminoglycoside ; Meropenem 1 g IV plus an aminoglycoside ; Imipenem-cilastatin 500 mg IV plus an aminoglycoside MEDICAL ONCOLOGY 19500 19500 19500 19500 19500 19500 19500 19500
CM0125-c : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0126 : THYROID CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0126-a : THYROID CANCER - sorafenib ; sorafenib 400 mg PO BID MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
CM0126-b : THYROID CANCER - sunitinib ; sunitinib 50 mg MEDICAL ONCOLOGY 28500 28500 28500 28500 28500 28500 28500 28500
CM0126-c : THYROID CANCER - pazopanib MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
CM0126-d : THYROID CANCER - Doxorubicin ; Doxorubicin 60 mg/m2 as monotherapy or in combination with cisplatin 40 mg/m2 MEDICAL ONCOLOGY 4400 4400 4400 4400 4400 4400 4400 4400
CM0126-e : THYROID CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0127 : THYMOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0127-a : THYMOMA - CAP ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 50mg/m2 IV, cyclophosphamide 500mg/m2 IV. ; Repeat every 21 days for a max of 8 cycles. MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
CM0127-b : THYMOMA - CAPP ; Day 1: Cyclophosphamide 500mg/m2 IV ; Days 1-3: Cisplatin 30mg/m2 IV ; Days 1-3: Doxorubicin 20mg/m2 ; Days 1-5: Prednisone 100mg. ; Repeat every 3 weeks for 3 cycles. MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
CM0127-c : THYMOMA - ADOC ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 40mg/m2 IV ; Day 3: Vincristine 0.6mg/m2 IV ; Day 4: Cyclophosphamide 700mg/m2 IV. ; Repeat every 3 weeks for 5 cycles. MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
CM0127-d : THYMOMA - PE ; Day 1: Cisplatin 60mg/m2 IV ; Days 1-3: Etoposide 120mg/m2 IV ; Repeat every 3 weeks for a max of 8 cycles. MEDICAL ONCOLOGY 5100 5100 5100 5100 5100 5100 5100 5100
CM0127-e : THYMOMA - VIP ; Days 1-4: Etoposide 75mg/m2 IV, ifosfamide 1.2g/m2 IV, cisplatin 20mg/m2 IV. ; Repeat every 3 weeks for 4 cycles MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
CM0127-f : THYMOMA - Carboplatin+paclitaxel ; Day 1: Paclitaxel 225mg/m2 IV, carboplatin AUC = 6 IV ; Repeat every 3 weeks for a max of 6 cycles. MEDICAL ONCOLOGY 9300 9300 9300 9300 9300 9300 9300 9300
CM0127-g : THYMOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0128 : BRAIN CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-i : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-i-a : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Combination PCV (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally. ; Days 8-21: Procarbazine 60mg/m2 orally once daily. ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
CM0128-i-b : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (7 weeks) ; Days 1-49: Temozolomide 75mg/m2 orally. ; Repeat cycle every 11 weeks (7 weeks on/4 weeks off) for 6 cycles. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0128-i-c : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide monthly 5-day course ; Temozolomide monthly 5-day courses at doses of 180 - 200mg/m2/day MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0128-i-d : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (3 weeks) ; Days 1-21: Temozolomide 75mg/m2/day orally. ; Repeat cycle every 28 days. MEDICAL ONCOLOGY 3400 3400 3400 3400 3400 3400 3400 3400
CM0128-ii : BRAIN CARCINOMA - Systemic Therapy for Anaplastic GliomasSystemic Therapy for Anaplastic Gliomas MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-ii-a : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Temozolomide monthly 5-day course ; Days 1-5: Temozolomide 200mg/m2/day orally. ; Repeat cycle every 4 weeks until disease progression or for up to 24 cycles. MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0128-ii-b : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV with deferred RT (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
CM0128-ii-c : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-ii-d : Adjuvant Temozolomide MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0128-ii-e : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV for 1p19q co-deleted (with Radiotherapy) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. for 6 cycles MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
CM0128-iii : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-iii-a : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
CM0128-iii-b : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Adjuvant Temozolomide (preceeded by Concurrent temozolzmide) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days for 6 cycles. MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0128-iii-c : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (post RT) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0128-iii-d : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (200mg) with standard RT ; Days 1-5: Temozolomide 200mg/m2, orally MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0128-iv : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-iv-a : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + lomustine ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; ; During Cranio-spinal RT MEDICAL ONCOLOGY 4400 4400 4400 4400 4400 4400 4400 4400
CM0128-iv-b : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV. MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
CM0128-v : BRAIN CARCINOMA - Primary CNS LymphomaPrimary CNS Lymphoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-v-a : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate combined with the following plus radiation therapyHigh dose methotrexate combined with the following plus radiation therapy MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-v-a-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + Cytarabine ; Day 1: MTX 3.5g/m2 ; Days 2-3: Cytarabine 2g/m2 IV twice a day. MEDICAL ONCOLOGY 6600 6600 6600 6600 6600 6600 6600 6600
CM0128-v-a-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + leucovorin + Ifosfamide + mesna ; Day 1: MTX 4gm/m2 IV, ; Days 2-5: leucovorin 20-25mg IV (upto 40mg) ; Days 3-5: Ifosfamide 1.5gm/m2 IV + mesna 400mg IV MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
CM0128-v-b : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate combined with the following plus radiation therapy High dose methotrexate (MTX 2.5-4.0mg/m2) + chemotherapy monoclonal antibody MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-v-b-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + MTX + vincristine +procarbazine ; Day 1: Rituximab 500mg/m2 IV ; Day 2: MTX 3.5mg/m2 IV plus vincristine 1.4mg/m2 ; Procarbazine 100mg/m2/day administered for 7 days with odd-numbered cycles MEDICAL ONCOLOGY 41900 41900 41900 41900 41900 41900 41900 41900
CM0128-v-c : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate (MTX 8.0mg/m2) + chemotherapy +/- monoclonal antibody High dose methotrexate (MTX 8.0mg/m2) + chemotherapy monoclonal antibody MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-v-c-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Induction ; MTX 8g/m2 IV ; Repeat every 2 weeks until complete response achieved or max of 8 cycles reached. ; MEDICAL ONCOLOGY 7900 7900 7900 7900 7900 7900 7900 7900
CM0128-v-c-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Consolidation ; MTX 8g/m2 IV administered ; Repeat every 2 weeks for 2 cycles. MEDICAL ONCOLOGY 7900 7900 7900 7900 7900 7900 7900 7900
CM0128-v-c-3-i : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (Cycles 1-4) ; Day 1: MTX 8g/m2 IV, Rituximab 375mg/m2 IV. ; Repeat every 4 weeks for 4 cycles MEDICAL ONCOLOGY 32400 32400 32400 32400 32400 32400 32400 32400
CM0128-v-c-3-ii : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (cycles 5-11) ; MTX 8g/m2 IV administered every 4 weeks for 11 cycles. ; Repeat cycle every 4 weeks for 4 cycles MEDICAL ONCOLOGY 7900 7900 7900 7900 7900 7900 7900 7900
CM0128-v-d : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-v-d-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - Induction ; Day 1: Rituximab 375mg/m2 IV, followed by ; Days 1-5: Temozolomide 150-200mg/m2 orally daily, after rituximab infusion. ; Repeat cycle every 4 weeks for 4 cycles. MEDICAL ONCOLOGY 26600 26600 26600 26600 26600 26600 26600 26600
CM0128-v-d-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - MaintananceDays 1-5: Temozolomide 150-200mg/m2 orally daily. ; Repeat cycle every 4 weeks for 8 cycles. MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
CM0128-v-e : BRAIN CARCINOMA - Meningioma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0128-v-e-1 : BRAIN CARCINOMA - Meningioma - Interferon-alfaInterferon-alfa ; alpha-IFN 106 units/m2 SC every other day for 4 weeks. ; Repeat cycle every 4 weeks. ; MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
CM0128-v-e-2 : BRAIN CARCINOMA - Meningioma -Somatostatin analog ; Sandostatin LAR Depot 10-30mg IM ; Repeat every 4 weeks. ; MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
CM0128-v-e-3 : BRAIN CARCINOMA - Meningioma - Sunitinib ; Days 1-28: Sunitinib 50mg orally daily. ; Repeat cycle every 42 days. MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
CM0129 : HEAD AND NECK CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0129-i : HEAD AND NECK CANCER - Squamous Cell Cancers MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0129-i-a : HEAD AND NECK CANCER - HIgh Dose Cisplatin ; Cisplatin 100mg/m2 IV + concurrent radiotherapy; Repeat cycle every 3 weeks for 3 cycles MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
CM0129-i-b : HEAD AND NECK CANCER - Carboplatin + infusional 5-FU ; Days 1-4: 5-FU 600mg/m2/day as continuous IV I, carboplatin 70mg/m2/day IV ; Repeat every 3 weeks for 3 cycles (given concurrently with radiotherapy). MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
CM0129-i-c : HEAD AND NECK CANCER - 5-FU + hydroxyurea ; Day 1: Hydroxyurea 1,000mg orally every 12 hours (11 doses/cycle), 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy MEDICAL ONCOLOGY 2300 2300 2300 2300 2300 2300 2300 2300
CM0129-i-d : HEAD AND NECK CANCER - Cisplatin + paclitaxel ; Day 1: Paclitaxel 30mg/m2 IV (every Monday), ; Day 2: Cisplatin 20mg/m2 IV (every Tuesday). ; Repeat cycle every week for 7 cycles, with Concurrent radiotherapy MEDICAL ONCOLOGY 3400 3400 3400 3400 3400 3400 3400 3400
CM0129-i-e : HEAD AND NECK CANCER - Cisplatin + infusional 5-FU ; Day 1: Cisplatin 60mg/m2 over ; Days 1-5: 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
CM0129-i-f : HEAD AND NECK CANCER - Carboplatin + paclitaxel ; Day 1: Paclitaxel 40-45mg/m2, carboplatin 100mg/m2 ; Repeat cycle every week for 8 cycles, with Concurrent radiotherapy MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
CM0129-i-g : HEAD AND NECK CANCER - Weekly cisplatin ; Cisplatin 40mg/m2 IV per week MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
CM0129-i-h : HEAD AND NECK CANCER - Cisplatin (For high risk oropharyngeal carcinoma) ; Days 1, 22, and 43: Cisplatin 100mg/m2 IV + radiotherapy. MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
CM0129-i-i : HEAD AND NECK CANCER - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV, ; Days 1-5: 5-FU 750mg/m2/day IV. ; Repeat every 3 weeks for up to 4 cycles. MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
CM0129-i-j : HEAD AND NECK CANCER - Paclitaxel + cisplatin+ infusional 5-FU ; Day 1: Paclitaxel 175mg/m2 ; Day 2: Cisplatin 100mg/m2 ; Day 2-6: 5-FU 500mg/m2/day IV ; Repeat every 3 weeks for 3 cycles. MEDICAL ONCOLOGY 7900 7900 7900 7900 7900 7900 7900 7900
CM0129-ii : HEAD AND NECK CANCER - Nasopharynx Cancer MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0129-ii-a : Nasopharynx Cancer - Concurrent Cisplatin followed by concurrent Cisplatin +5FUC ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0129-ii-a-1 : Nasopharynx Cancer - Concurrent Cisplatin (followed by concurrent Cisplatin +5FU) ; Day 1: Cisplatin 100mg/m2 IV; plus radiotherapy. ; Repeat cycle every 3 weeks for 3 cycles; followed by concurrent Cisplatin +5FU MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
CM0129-ii-a-2 : Nasopharynx Cancer - concurrent Cisplatin +5FU - Preceeded by (Concurrent Cisplatin 3 cycles) ; Days 1-4: Cisplatin 80mg/m2/day, 5-FU 1,000mg/m2/day IV ; Repeat cycle every 4 weeks for 3 cycles MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
CM0129-ii-b : Nasopharynx Cancer - Concurrent Carboplatin followed by concurrent Carboplatin +5FU MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0129-ii-b-1 : Nasopharynx Cancer - Concurrent Carboplatin - (followed by concurrent Carboplatin +5FU) ; Day 1: Carboplatin AUC 6mg/min/mL IV. ; Repeat cycle every 3 weeks for 3 cycles; MEDICAL ONCOLOGY 4300 4300 4300 4300 4300 4300 4300 4300
CM0129-ii-b-2 : Nasopharynx Cancer - concurrent Carboplatin +5FU - Preceeded by (Concurrent Carboplatin ) ; Day 1: Carboplatin AUC 5mg/min/mL IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. MEDICAL ONCOLOGY 13500 13500 13500 13500 13500 13500 13500 13500
CM0129-ii-c : Nasopharynx Cancer - Concurrent Cisplatin ; Cisplatin 40mg/m2 ; Repeat weekly for 7 cycles MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
CM0129-ii-d : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU followed by Cisplatin ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0129-ii-d-1 : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU - followed by Cisplatin after 3 cycles ; Day 1: Docetaxel 70mg/m2 IV, cisplatin 75mg/m2 IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat every week for 3 cycles MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
CM0129-ii-d-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 3 cycles of Docetaxel + 5-FU ; Day 1: Cisplatin 100mg/m2; ; Repeat every 3 weeks, Till radiation MEDICAL ONCOLOGY 2800 2800 2800 2800 2800 2800 2800 2800
CM0129-ii-e : Nasopharynx Cancer - Docetaxel + cisplatin MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0129-ii-e-1 : Nasopharynx Cancer - Docetaxel + cisplatin - followed by Cisplatin after 2 cycles ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV ; Repeat every 3 weeks for two cycles MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
CM0129-ii-e-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 2 cycles of Docetaxel + cisplatin ; Cisplatin 40mg/m2 IV ; weekly concurrent with radiotherapy. MEDICAL ONCOLOGY 2300 2300 2300 2300 2300 2300 2300 2300
CM0129-ii-f : Nasopharynx Cancer - Cisplatin + 5-FU ; Day 1: Cisplatin 100mg/m2/day IV. ; Days 1-4: 5-FU 1,000mg/m2/day continuous IV infusion for 4 days. ; Repeat cycle every 3 weeks for a minimum of 6 cycles MEDICAL ONCOLOGY 5100 5100 5100 5100 5100 5100 5100 5100
CM0129-iii : HEAD AND NECK CANCER (or) Nasopharynx Cancer - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0130 : RENAL CELL CARCINOMARENAL CELL CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0130-a : Pazopanib MEDICAL ONCOLOGY 19000 19000 19000 19000 19000 19000 19000 19000
CM0130-b : Sunitinib MEDICAL ONCOLOGY 29000 29000 29000 29000 29000 29000 29000 29000
CM0130-c : Sorafenib MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
CM0130-d : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0131 : UNKNOWN PRIMARYUNKNOWN PRIMARY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0131-i : UNKNOWN PRIMARY - Adenocarcinoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0131-i-a : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin + etoposide ; Day 1: Paclitaxel 200 mg/m 2 IV, carboplatin AUC 6 ; Days 1-10: etoposide 50 mg PO alternating with 100 mg daily ; Repeat every 21days for 2-3 cycles; restage, can be treated upto 8 cycles MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
CM0131-i-b : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin ; Day 1: Paclitaxel 200 mg/m 2, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
CM0131-i-c : UNKNOWN PRIMARY - Adenocarcinoma - Docetaxel + carboplatin ; Day 1: Docetaxel 65mg/m2 IV, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles. MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
CM0131-i-d : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + cisplatin ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat cycle every 3 weeks for 4 cycles. MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
CM0131-i-e : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + docetaxel ; Day 1 and 8: Gemcitabine 1000mg/m2 IV over 30 minutes ; Day 8: Docetaxel 75mg/m2 IV ; Repeat cycle every 3 weeks for a maximum of 6 cycles MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
CM0131-i-f : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + irinotecan ; Days 1 and 8: Irinotecan 100mg/m2 IV, gemcitabine 1000mg/m2 IV. ; Repeat cycle every 3 weeks for 6 cycles.restage every 2-3 cycles MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
CM0131-ii : UNKNOWN PRIMARY - Squamous cell carcinoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0131-ii-a : UNKNOWN PRIMARY - Squamous cell carcinoma - Paclitaxel + cisplatin + 5-FU ; Paclitaxel 175 mg/m 2 IV, ; Day 2: cisplatin 100 mg/m 2 IV, ; Day 5-FU (5-fluorouracil) 500 mg/m 2/day IV ; Repeat every 21d MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
CM0131-ii-b : UNKNOWN PRIMARY - Squamous cell carcinoma - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Days 1-5: 5-FU 750mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
CM0131-iii : UNKNOWN PRIMARY - Neuroendocrine tumors MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0131-iii-b : UNKNOWN PRIMARY - Neuroendocrine tumors - Etoposide + cisplatin ; Days 1-3: Etoposide 100 mg/m 2 ; Days 2-3: cisplatin 45 mg/m 2 IV ; Repeat every 28 days MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
CM0131-iv : UNKNOWN PRIMARY - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0132 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0132-a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Gemcitabine + cisplatin ; Days 1 and 8: Cisplatin 25mg/m2 IV, gemcitabine 1,000mg/m2 IV ; Repeat every 21 days for 4 cycles, re-evaluate and continue an additional 4 cycles if warranted MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
CM0132-b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV MEDICAL ONCOLOGY 4100 4100 4100 4100 4100 4100 4100 4100
CM0132-c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Capecitabine ; Capecitabine oral ; Repeat every 21 days MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
CM0132-d : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0133 : PANCREAS CARCINOMAPANCREAS CARCINOMA - MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0133-i : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0133-i-a : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV ; Repeat every 4 weeks for six cycles MEDICAL ONCOLOGY 6600 6600 6600 6600 6600 6600 6600 6600
CM0133-ii : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0133-ii-a : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - 5-FU + Leucovorin ; Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2 IV ; Repeat cycle every 4 weeks MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
CM0133-ii-b : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Gemcitabine & 5FU ; Prior to chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 4 weeks for 3 months. MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
CM0133-ii-c : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Continuous infusion 5-FU (with Radiation) ; Prior to chemoradiation: ; Days 1-21: 5-FU 250mg/m2/day continuous IV infusion; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1-28: 5-FU 250mg/m2/day continuous IV infusion; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 6 weeks for 3 months. MEDICAL ONCOLOGY 20700 20700 20700 20700 20700 20700 20700 20700
CM0133-iii : PANCREAS CARCINOMA - Neoadjuvant therapy - Neoadjuvant therapy MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0133-iii-a : PANCREAS CARCINOMA - Neoadjuvant therapy - CapecitabineCapecitabine ; Capecitabine ; Repeat cycle every 3 weeks for up to 52 weeks. MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
CM0133-iv : PANCREAS CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0134 : PERI AMPULLARY CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0134-a : PERI AMPULLARY CARCINOMA - 5-FU ; Fluorouracil 425 mg/m2 administered on days 1 to 5 and 29-33 MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
CM0134-b : PERI AMPULLARY CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0135 : NEURO ENDOCRINE CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0135-a : NEURO ENDOCRINE CARCINOMA - All NECs are covered under Organ Cancers. If uncovered - Unlisted only. MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0135-b : NEURO ENDOCRINE CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0136 : SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0136-i : SARCOMA - Gastrointestinal Stromal Tumor - GIST MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0136-i-a : SARCOMA - Gastrointestinal Stromal Tumor - GIST - Imatinib ; Imatinib 400mg orally once daily to twice daily MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
CM0136-ii : SARCOMA - SOFT TISSUE SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0136-ii-a : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + dacarbazine (AD) ; Days 1-4: Doxorubicin 60mg/m2 + dacarbazine 750mg/m2 ; Repeat cycle every 3 weeks MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
CM0136-ii-b : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + ifosfamide + mesna ; Days 1 and 2: Doxorubicin 30mg/m2/day IV, ifosfamide 3,750mg/m2/day IV, mesna 750mg/m2 IV ; Repeat cycle every 3 weeks MEDICAL ONCOLOGY 9200 9200 9200 9200 9200 9200 9200 9200
CM0136-ii-c : SARCOMA - SOFT TISSUE SARCOMA - Mesna + doxorubicin + ifosfamide + dacarbazine (MAID) ; Days 1-3: Doxorubicin 20mg/m2/day, ifosfamide 2,500mg/m2/day, dacarbazine 300mg/m2/day IV ; Days 1-4: Mesna 2,500mg/m2/day IV for 84 to 96 hours. ; Repeat cycle every 3 weeks. MEDICAL ONCOLOGY 10700 10700 10700 10700 10700 10700 10700 10700
CM0136-ii-d : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide + epirubicin + mesna ; Days 1 and 2: Epirubicin 60mg/m2/day IV ; Days 1-5: Ifosfamide 1.8g/m2/day IV + mesna. ; Repeat cycle every 3 weeks for 5 cycles. MEDICAL ONCOLOGY 12800 12800 12800 12800 12800 12800 12800 12800
CM0136-ii-e : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + docetaxel ; Days 1 and 8: Gemcitabine 900mg/m2 IV ; Day 8: Docetaxel 100mg/m2 IV. ; Repeat cycle every 3 weeks MEDICAL ONCOLOGY 5100 5100 5100 5100 5100 5100 5100 5100
CM0136-ii-f : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + vinorelbine ; Days 1 and 8: Vinorelbine 25mg/m2 IV, gemcitabine 800mg/m2 IV ; Repeat cycle every 3 weeks MEDICAL ONCOLOGY 14700 14700 14700 14700 14700 14700 14700 14700
CM0136-ii-g : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + dacarbazine ; Day 1: Gemcitabine 1,800mg/m2 IV + dacarbazine 500mg/m2 IV. ; Repeat cycle ever 2 weeks for a total of 12 cycles; MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
CM0136-ii-h : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin ; Doxorubicin 60-75mg/m2 IV ; once every 3 weeks MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
CM0136-ii-i : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Days 1-3: Ifosfamide 2,000-3,000mg/m2/day IV for 3 to 4 days + mesna ; Repeat every 3 weeks. MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0136-ii-j : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Day 1: Ifosfamide 5,000mg/m2 + mesna 5,000mg/m2 IV ; Day 2: mesna 400-600mg/m2 IV ; Ifosfamide, mesna ; Repeat every 3 weeks MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
CM0136-ii-k : SARCOMA - SOFT TISSUE SARCOMA - Epirubicin ; Epirubicin 160mg/m2 IV ; Repeat every 3 weeks MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
CM0136-ii-l : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine ; Days 1 and 8: Gemcitabine 1,200mg/m2 IV ; Repeat cycle every 3 weeks. MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
CM0136-ii-m : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (i) ; Dacarbazine 250mg/m2/day IV for 5 days ; Repeat every 3 weeks. MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
CM0136-ii-n : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (ii) ; Dacarbazine 800-1,000mg/m2 IV ; Repeat every 3 weeks. MEDICAL ONCOLOGY 2400 2400 2400 2400 2400 2400 2400 2400
CM0136-ii-o : SARCOMA - SOFT TISSUE SARCOMA - Liposomal doxorubicin ; Liposomal doxorubicin 30-50mg/m2 IV ; Repeat every 4 weeks. MEDICAL ONCOLOGY 7900 7900 7900 7900 7900 7900 7900 7900
CM0136-ii-p : SARCOMA - SOFT TISSUE SARCOMA - Temozolomide ; Temozolomide 200mg/m2 orally twice daily for 5 days, followed by 9 doses of 90mg/m2 orally ; Repeat every 4 weeks MEDICAL ONCOLOGY 4200 4200 4200 4200 4200 4200 4200 4200
CM0136-iii : SARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0137 : PRIMITIVE NEURO ECTODERMAL TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0137-a : PRIMITIVE NEURO ECTODERMAL TUMOR - Weekly vincristine ; vincristine 1.5mg/m2 IV, max 2mg ; for 5 to 6 weeks MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
CM0137-b : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + lomustine ; During craniospinal radiotherapy (RT) ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; up to max 8 doses MEDICAL ONCOLOGY 4400 4400 4400 4400 4400 4400 4400 4400
CM0137-c : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV, max 2mg ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
CM0137-d : PRIMITIVE NEURO ECTODERMAL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0137-vi : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0138 : MELANOMA - No primary regimens only RT. For advanced unresectable and metastatic disease - Pallitive Chemotherapy MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0139 : ANAL CANAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0139-a : ANAL CANAL CANCER - 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day IV ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), with Concurrent radiotherapy MEDICAL ONCOLOGY 11400 11400 11400 11400 11400 11400 11400 11400
CM0139-b : ANAL CANAL CANCER - Capecitabine + Mitomycin (i) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus, with Concurrent radiotherapy. MEDICAL ONCOLOGY 8100 8100 8100 8100 8100 8100 8100 8100
CM0139-c : ANAL CANAL CANCER - Capecitabine + Mitomycin (ii) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Day 1: Mitomycin 12mg/m2 IV bolus, with Concurrent radiotherapy MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
CM0139-d : ANAL CANAL CANCER - Cisplatin + 5-FU ; Days 1-5: 5-FU 1,000mg/m2/day IV ; Day 2: Cisplatin 100mg/m2 IV ; Repeat cycle every 4 weeks, with Concurrent radiotherapy MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
CM0139-e : ANAL CANAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A : All Leukemia ( Chemotheraphy) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-I : Chronic Myeloid Leukemia (CML) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-I-i-a : Imatinib MEDICAL ONCOLOGY 1525 1525 1525 1525 1525 1525 1525 1525
CM0952A-I-i-b : Nilotinib MEDICAL ONCOLOGY 17800 17800 17800 17800 17800 17800 17800 17800
CM0952A-I-ii : Blast phase-Lymphoid ALL Type Induction + TKI MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-I-ii-a : Induction MEDICAL ONCOLOGY 12840 12840 12840 12840 12840 12840 12840 12840
CM0952A-I-ii-b : Imatinib MEDICAL ONCOLOGY 1525 1525 1525 1525 1525 1525 1525 1525
CM0952A-I-ii-c : Nilotinib MEDICAL ONCOLOGY 17800 17800 17800 17800 17800 17800 17800 17800
CM0952A-I-iii : Blast phase-myeloid AML Type Induction + TKI MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-I-iii-a : Daunorubicin (90mg/m2)+ Cytarabine MEDICAL ONCOLOGY 12320 12320 12320 12320 12320 12320 12320 12320
CM0952A-I-iii-b : Daunorubicin + Cytarabine + Cladribine MEDICAL ONCOLOGY 10365 10365 10365 10365 10365 10365 10365 10365
CM0952A-I-iii-c : Daunorubicin + Cytarabine (High Dose) MEDICAL ONCOLOGY 16725 16725 16725 16725 16725 16725 16725 16725
CM0952A-I-iii-d : Daunorubicin (90mg) + Cytarabine MEDICAL ONCOLOGY 12320 12320 12320 12320 12320 12320 12320 12320
CM0952A-I-iii-e : Idarubicin + Cytarabine (High Dose) MEDICAL ONCOLOGY 29600 29600 29600 29600 29600 29600 29600 29600
CM0952A-I-iii-f : Idarubicin + Cytarabine MEDICAL ONCOLOGY 23240 23240 23240 23240 23240 23240 23240 23240
CM0952A-I-iii-g : mitoxantrone + Cytarabine MEDICAL ONCOLOGY 10820 10820 10820 10820 10820 10820 10820 10820
CM0952A-I-iii-h : Imatinib MEDICAL ONCOLOGY 1525 1525 1525 1525 1525 1525 1525 1525
CM0952A-I-iii-i : Nilotinib MEDICAL ONCOLOGY 17800 17800 17800 17800 17800 17800 17800 17800
CM0952A-I-iii-ii : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952A-I-iii-iii : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952A-II : Acute Myeloid Leukemia (AML) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-II-a : Daunorubicin + Cytarabine 1 MEDICAL ONCOLOGY 12320 12320 12320 12320 12320 12320 12320 12320
CM0952A-II-b : Idarubicin + Cytarabine MEDICAL ONCOLOGY 23240 23240 23240 23240 23240 23240 23240 23240
CM0952A-II-c : Daunorubicin + Cytarabine 2 MEDICAL ONCOLOGY 10365 10365 10365 10365 10365 10365 10365 10365
CM0952A-II-d : Daunorubicin + Cytarabine (High Dose) MEDICAL ONCOLOGY 16725 16725 16725 16725 16725 16725 16725 16725
CM0952A-II-e : Idarubicin + Cytarabine (High Dose) MEDICAL ONCOLOGY 29600 29600 29600 29600 29600 29600 29600 29600
CM0952A-II-f : Daunorubicin (90mg) + Cytarabine MEDICAL ONCOLOGY 12320 12320 12320 12320 12320 12320 12320 12320
CM0952A-II-g : idarubicin + Cytarabine MEDICAL ONCOLOGY 23240 23240 23240 23240 23240 23240 23240 23240
CM0952A-II-h : mitoxantrone + Cytarabine MEDICAL ONCOLOGY 10280 10280 10280 10280 10280 10280 10280 10280
CM0952A-II-i : Cytarabine MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
CM0952A-II-j : Decitabine MEDICAL ONCOLOGY 25000 25000 25000 25000 25000 25000 25000 25000
CM0952A-II-k : azacytidine MEDICAL ONCOLOGY 77500 77500 77500 77500 77500 77500 77500 77500
CM0952A-II-l : Hydroxyurea MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
CM0952A-II-m : Cytarabine - High Dose MEDICAL ONCOLOGY 9720 9720 9720 9720 9720 9720 9720 9720
CM0952A-II-n : Cladribine + Cytarabine + Idarubicin + Gcsf MEDICAL ONCOLOGY 85150 85150 85150 85150 85150 85150 85150 85150
CM0952A-II-o : Cladribine + Cytarabine + Mitoxantrone + Gcsf MEDICAL ONCOLOGY 40690 40690 40690 40690 40690 40690 40690 40690
CM0952A-II-p : Fludarabine + Cytarabine + Idarubicin + Gcsf MEDICAL ONCOLOGY 66710 66710 66710 66710 66710 66710 66710 66710
CM0952A-II-q : Etoposide +Cytarabine+Mitoxantrone MEDICAL ONCOLOGY 13260 13260 13260 13260 13260 13260 13260 13260
CM0952A-II-r : Cytarabine SC MEDICAL ONCOLOGY 2800 2800 2800 2800 2800 2800 2800 2800
CM0952A-II-s : azacytidine MEDICAL ONCOLOGY 77500 77500 77500 77500 77500 77500 77500 77500
CM0952A-II-t : Decitabine MEDICAL ONCOLOGY 25500 25500 25500 25500 25500 25500 25500 25500
CM0952A-II-u : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952A-III : Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-III-a-i : Rituximab + chlorambucil Cycle 1 MEDICAL ONCOLOGY 1084 1084 1084 1084 1084 1084 1084 1084
CM0952A-III-a-ii : Rituximab + chlorambucil Cycle 3 MEDICAL ONCOLOGY 25584 25584 25584 25584 25584 25584 25584 25584
CM0952A-III-a-iii : Rituximab + chlorambucil Cycle 4-8 MEDICAL ONCOLOGY 32984 32984 32984 32984 32984 32984 32984 32984
CM0952A-III-a-iv : Maintanance - Rituximab MEDICAL ONCOLOGY 25500 25500 25500 25500 25500 25500 25500 25500
CM0952A-III-b : Rituximab Day 1, 8, 15, and 22: MEDICAL ONCOLOGY 100500 100500 100500 100500 100500 100500 100500 100500
CM0952A-III-c : Chlorambucil MEDICAL ONCOLOGY 2344 2344 2344 2344 2344 2344 2344 2344
CM0952A-III-d-i : Bendamustine + Rituximab (Cycle -1) MEDICAL ONCOLOGY 36500 36500 36500 36500 36500 36500 36500 36500
CM0952A-III-d-ii : Bendamustine + Rituximab (Cycles 2-6) MEDICAL ONCOLOGY 37900 37900 37900 37900 37900 37900 37900 37900
CM0952A-III-d-iii : Bendamustine (70mg) (Cycle -1) MEDICAL ONCOLOGY 12500 12500 12500 12500 12500 12500 12500 12500
CM0952A-III-d-iv : Bendamustine (90 mg) (Cycles 2-6) MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0952A-III-e : Fludarabine + cyclophosphamide + rituximab (FCR) MEDICAL ONCOLOGY 31898 31898 31898 31898 31898 31898 31898 31898
CM0952A-III-f : Fludarabine + rituximab (FR) MEDICAL ONCOLOGY 67930 67930 67930 67930 67930 67930 67930 67930
CM0952A-III-g : Alemtuzumab + rituximab MEDICAL ONCOLOGY 108950 108950 108950 108950 108950 108950 108950 108950
CM0952A-III-h : Alemtuzumab without rituximab MEDICAL ONCOLOGY 11450 11450 11450 11450 11450 11450 11450 11450
CM0952A-III-i : High-dose methylprednisolone + rituximab MEDICAL ONCOLOGY 103955 103955 103955 103955 103955 103955 103955 103955
CM0952A-III-j : High-dose methylprednisolone MEDICAL ONCOLOGY 6455 6455 6455 6455 6455 6455 6455 6455
CM0952A-III-k : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952A-IV : Acute Lymphoblastic Leukemia (ALL) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-IV-i : Ph(+) AYA (Age 15-39 years) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-IV-i-a-1 : Childrens Oncology Group (COG) AALL-0031 INDUCTION PHASE MEDICAL ONCOLOGY 13340 13340 13340 13340 13340 13340 13340 13340
CM0952A-IV-i-a-2 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 MEDICAL ONCOLOGY 17095 17095 17095 17095 17095 17095 17095 17095
CM0952A-IV-i-a-3 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 MEDICAL ONCOLOGY 19175 19175 19175 19175 19175 19175 19175 19175
CM0952A-IV-i-a-4 : Childrens Oncology Group (COG) AALL-0031 REINDUCTION MEDICAL ONCOLOGY 25291 25291 25291 25291 25291 25291 25291 25291
CM0952A-IV-i-a-5 : Childrens Oncology Group (COG) AALL-0031 INTENSIFICATION MEDICAL ONCOLOGY 41425 41425 41425 41425 41425 41425 41425 41425
CM0952A-IV-i-a-6 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 1-4 (8 weeks) MEDICAL ONCOLOGY 35621 35621 35621 35621 35621 35621 35621 35621
CM0952A-IV-i-a-7 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 5-12 (8 weeks) MEDICAL ONCOLOGY 12836 12836 12836 12836 12836 12836 12836 12836
CM0952A-IV-i-b-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) MEDICAL ONCOLOGY 59429 59429 59429 59429 59429 59429 59429 59429
CM0952A-IV-i-b-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) MEDICAL ONCOLOGY 62380 62380 62380 62380 62380 62380 62380 62380
CM0952A-IV-i-b-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) MEDICAL ONCOLOGY 11469 11469 11469 11469 11469 11469 11469 11469
CM0952A-IV-i-b-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) MEDICAL ONCOLOGY 13420 13420 13420 13420 13420 13420 13420 13420
CM0952A-IV-i-b-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II MEDICAL ONCOLOGY 15133 15133 15133 15133 15133 15133 15133 15133
CM0952A-IV-i-b-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III MEDICAL ONCOLOGY 5535 5535 5535 5535 5535 5535 5535 5535
CM0952A-IV-i-b-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance MEDICAL ONCOLOGY 9923 9923 9923 9923 9923 9923 9923 9923
CM0952A-IV-i-c-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE MEDICAL ONCOLOGY 15133 15133 15133 15133 15133 15133 15133 15133
CM0952A-IV-i-c-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I MEDICAL ONCOLOGY 8460 8460 8460 8460 8460 8460 8460 8460
CM0952A-IV-i-c-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
CM0952A-IV-i-c-4 : Multiagent Chemotherapy + TKIs MAINTENANCE MEDICAL ONCOLOGY 3410 3410 3410 3410 3410 3410 3410 3410
CM0952A-IV-i-c-5 : Imatinib MEDICAL ONCOLOGY 1525 1525 1525 1525 1525 1525 1525 1525
CM0952A-IV-i-c-6 : Nilotinib MEDICAL ONCOLOGY 17800 17800 17800 17800 17800 17800 17800 17800
CM0952A-IV-i-d : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952A-IV-ii : Ph(+) AYA (Age > 40 years) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-IV-ii-a-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) MEDICAL ONCOLOGY 59429 59429 59429 59429 59429 59429 59429 59429
CM0952A-IV-ii-a-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) MEDICAL ONCOLOGY 62380 62380 62380 62380 62380 62380 62380 62380
CM0952A-IV-ii-a-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) MEDICAL ONCOLOGY 11469 11469 11469 11469 11469 11469 11469 11469
CM0952A-IV-ii-a-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) MEDICAL ONCOLOGY 13420 13420 13420 13420 13420 13420 13420 13420
CM0952A-IV-ii-a-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II MEDICAL ONCOLOGY 15133 15133 15133 15133 15133 15133 15133 15133
CM0952A-IV-ii-a-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III MEDICAL ONCOLOGY 5535 5535 5535 5535 5535 5535 5535 5535
CM0952A-IV-ii-a-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance MEDICAL ONCOLOGY 9923 9923 9923 9923 9923 9923 9923 9923
CM0952A-IV-ii-b-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE MEDICAL ONCOLOGY 15573 15573 15573 15573 15573 15573 15573 15573
CM0952A-IV-ii-b-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I MEDICAL ONCOLOGY 12110 12110 12110 12110 12110 12110 12110 12110
CM0952A-IV-ii-b-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
CM0952A-IV-ii-b-4 : Multiagent Chemotherapy + TKIs MAINTENANCE MEDICAL ONCOLOGY 6410 6410 6410 6410 6410 6410 6410 6410
CM0952A-IV-ii-b-5 : Imatinib MEDICAL ONCOLOGY 1525 1525 1525 1525 1525 1525 1525 1525
CM0952A-IV-ii-b-6 : Nilotinib MEDICAL ONCOLOGY 17800 17800 17800 17800 17800 17800 17800 17800
CM0952A-IV-ii-c : Corticosteroids + TKIs MEDICAL ONCOLOGY 9035 9035 9035 9035 9035 9035 9035 9035
CM0952A-IV-ii-d : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952A-IV-iii : Ph(-) AYA (Age 15-39 years) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-IV-iii-a-1 : GRAALL-2003 INDUCTION MEDICAL ONCOLOGY 15678 15678 15678 15678 15678 15678 15678 15678
CM0952A-IV-iii-a-2 : GRAALL-2003 SALVAGE MEDICAL ONCOLOGY 28760 28760 28760 28760 28760 28760 28760 28760
CM0952A-IV-iii-a-3 : GRAALL-2003 CONSOLIDATION MEDICAL ONCOLOGY 30779 30779 30779 30779 30779 30779 30779 30779
CM0952A-IV-iii-a-4 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in complete remission [CR] after the first induction course) MEDICAL ONCOLOGY 15495 15495 15495 15495 15495 15495 15495 15495
CM0952A-IV-iii-a-5 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in CR after salvage course) MEDICAL ONCOLOGY 27210 27210 27210 27210 27210 27210 27210 27210
CM0952A-IV-iii-a-6 : GRAALL-2003 Maintenance MEDICAL ONCOLOGY 56898 56898 56898 56898 56898 56898 56898 56898
CM0952A-IV-iii-b : CNS Therapy-Treatment of patients with initial CNS involvement: MEDICAL ONCOLOGY 21155 21155 21155 21155 21155 21155 21155 21155
CM0952A-IV-iii-v : CCG-1961 MEDICAL ONCOLOGY 18310 18310 18310 18310 18310 18310 18310 18310
CM0952A-IV-iii-vi : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952A-IV-iv : Ph(-) AYA (Age > 40 years) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0952A-IV-iv-a-1 : CALGB 8811 (Larson Regimen) INDUCTION MEDICAL ONCOLOGY 18038 18038 18038 18038 18038 18038 18038 18038
CM0952A-IV-iv-a-2 : CALGB 8811 (Larson Regimen) CONSOLIDATION MEDICAL ONCOLOGY 16685 16685 16685 16685 16685 16685 16685 16685
CM0952A-IV-iv-b-1 : Hyper-CVAD with or without Rituximab CYCLE 1,3,5,7 MEDICAL ONCOLOGY 60970 60970 60970 60970 60970 60970 60970 60970
CM0952A-IV-iv-b-2 : Hyper-CVAD with or without Rituximab CYCLE 2,4,6,8 MEDICAL ONCOLOGY 56820 56820 56820 56820 56820 56820 56820 56820
CM0952A-IV-iii-c : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A : All Lymphoma Chemotheraphy MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-I : Hodgkins Lymphoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-I-a : ABVD MEDICAL ONCOLOGY 4480 4480 4480 4480 4480 4480 4480 4480
CM0953A-I-b : Escalated BEACOPP MEDICAL ONCOLOGY 7119 7119 7119 7119 7119 7119 7119 7119
CM0953A-I-c : ABVD + Rituximab (cyled every 4 weeks) MEDICAL ONCOLOGY 28480 28480 28480 28480 28480 28480 28480 28480
CM0953A-I-d-i : ABVD + Rituximab (1 cycle - weekly rituximab 4 doses) followed by ABVD MEDICAL ONCOLOGY 102480 102480 102480 102480 102480 102480 102480 102480
CM0953A-I-d-ii : ABVD MEDICAL ONCOLOGY 4480 4480 4480 4480 4480 4480 4480 4480
CM0953A-I-e-i : CHOP + Rituximab MEDICAL ONCOLOGY 26818 26818 26818 26818 26818 26818 26818 26818
CM0953A-I-e-ii : CHOP MEDICAL ONCOLOGY 2818 2818 2818 2818 2818 2818 2818 2818
CM0953A-I-f-i : CVP +/- Rituximab MEDICAL ONCOLOGY 25768 25768 25768 25768 25768 25768 25768 25768
CM0953A-I-f-ii : CVP MEDICAL ONCOLOGY 1768 1768 1768 1768 1768 1768 1768 1768
CM0953A-I-g : Rituximab MEDICAL ONCOLOGY 25500 25500 25500 25500 25500 25500 25500 25500
CM0953A-I-h : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A-II : Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-II-a : Bortezomib + dexamethasone MEDICAL ONCOLOGY 68038 68038 68038 68038 68038 68038 68038 68038
CM0953A-II-b : Cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab MEDICAL ONCOLOGY 26818 26818 26818 26818 26818 26818 26818 26818
CM0953A-II-c : Rituximab MEDICAL ONCOLOGY 25500 25500 25500 25500 25500 25500 25500 25500
CM0953A-II-d : Rituximab + cyclophosphamide + prednisone MEDICAL ONCOLOGY 25738 25738 25738 25738 25738 25738 25738 25738
CM0953A-II-e : Rituximab + cyclophosphamide + dexamethasone MEDICAL ONCOLOGY 25520 25520 25520 25520 25520 25520 25520 25520
CM0953A-II-f-i : Thalidomide with or without rituximab (Weeks 1 and 2) MEDICAL ONCOLOGY 2540 2540 2540 2540 2540 2540 2540 2540
CM0953A-II-f-ii : Thalidomide with or without rituximab (Weeks 3-50) MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
CM0953A-II-f-iii : Thalidomide with or without rituximab (Weeks 50-52) MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
CM0953A-II-f-iv : Thalidomide with or without rituximab Weeks 2-5 and 13-16 MEDICAL ONCOLOGY 24000 24000 24000 24000 24000 24000 24000 24000
CM0953A-II-g-i : Bendamustine with or without rituximab MEDICAL ONCOLOGY 36500 36500 36500 36500 36500 36500 36500 36500
CM0953A-II-g-ii : Bendamustine - rituximab MEDICAL ONCOLOGY 12500 12500 12500 12500 12500 12500 12500 12500
CM0953A-II-h-i : Cladribine with or without rituximab MEDICAL ONCOLOGY 32250 32250 32250 32250 32250 32250 32250 32250
CM0953A-II-h-ii : Cladribine - rituximab MEDICAL ONCOLOGY 8250 8250 8250 8250 8250 8250 8250 8250
CM0953A-II-i : Bendamustine MEDICAL ONCOLOGY 12500 12500 12500 12500 12500 12500 12500 12500
CM0953A-II-j : Chlorambucil MEDICAL ONCOLOGY 1126 1126 1126 1126 1126 1126 1126 1126
CM0953A-II-k : Fludarabine MEDICAL ONCOLOGY 12030 12030 12030 12030 12030 12030 12030 12030
CM0953A-II-l : Fludarabine + cyclophosphamide + rituximab (FCR) MEDICAL ONCOLOGY 32398 32398 32398 32398 32398 32398 32398 32398
CM0953A-II-m : Alemtuzumab MEDICAL ONCOLOGY 2650 2650 2650 2650 2650 2650 2650 2650
CM0953A-II-n : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A-III : NON HODGKINS LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-III-i : BURKITT LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-III-i-a -1 : CALGB 10002 Cycle 1: MEDICAL ONCOLOGY 8967 8967 8967 8967 8967 8967 8967 8967
CM0953A-III-i-a-2 : CALGB 10002 Cycles 2 (beginning Day 8), 4, and 6: MEDICAL ONCOLOGY 66113 66113 66113 66113 66113 66113 66113 66113
CM0953A-III-i-a-3 : CALGB 10002 Cycles 3, 5, and 7: MEDICAL ONCOLOGY 33108 33108 33108 33108 33108 33108 33108 33108
CM0953A-III-i-a-4 : CALGB 10002 Cycles 4, and 6: MEDICAL ONCOLOGY 36413 36413 36413 36413 36413 36413 36413 36413
CM0953A-III-i-b : CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine with intrathecal MTX + cytarabine, followed by systemic MTX and cytarabine) with or without Rituximab MEDICAL ONCOLOGY 46780 46780 46780 46780 46780 46780 46780 46780
CM0953A-III-i-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1 & 2) MEDICAL ONCOLOGY 32972 32972 32972 32972 32972 32972 32972 32972
CM0953A-III-i-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) MEDICAL ONCOLOGY 32572 32572 32572 32572 32572 32572 32572 32572
CM0953A-III-i-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) MEDICAL ONCOLOGY 59429 59429 59429 59429 59429 59429 59429 59429
CM0953A-III-i-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) MEDICAL ONCOLOGY 61880 61880 61880 61880 61880 61880 61880 61880
CM0953A-III-i-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) MEDICAL ONCOLOGY 10969 10969 10969 10969 10969 10969 10969 10969
CM0953A-III-i-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) MEDICAL ONCOLOGY 12920 12920 12920 12920 12920 12920 12920 12920
CM0953A-III-i-e-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab MEDICAL ONCOLOGY 46780 46780 46780 46780 46780 46780 46780 46780
CM0953A-III-i-e-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab MEDICAL ONCOLOGY 42847 42847 42847 42847 42847 42847 42847 42847
CM0953A-III-i-f : RICE (rituximab + ifosfamide + carboplatin + etoposide) MEDICAL ONCOLOGY 32994 32994 32994 32994 32994 32994 32994 32994
CM0953A-III-i-g : RIVAC (rituximab + ifosfamide + cytarabine + etoposide) MEDICAL ONCOLOGY 43894 43894 43894 43894 43894 43894 43894 43894
CM0953A-III-i-h : RGDP (rituximab + gemcitabine + dexamethasone + cisplatin) MEDICAL ONCOLOGY 32255 32255 32255 32255 32255 32255 32255 32255
CM0953A-III-i-i : HDAC + Rituximab MEDICAL ONCOLOGY 27800 27800 27800 27800 27800 27800 27800 27800
CM0953A-III-i-ii : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A-III-ii : NON HODGKIN LYMPHOMA -- ADULT T-CELL LEUKEMIA / LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-III-ii-a-1 : Zidovudine + alpha-interferon (induction) MEDICAL ONCOLOGY 4580 4580 4580 4580 4580 4580 4580 4580
CM0953A-III-ii-a-2 : Zidovudine + alpha-interferon (Maintenance Therapy) MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0953A-III-ii-b : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) MEDICAL ONCOLOGY 2818 2818 2818 2818 2818 2818 2818 2818
CM0953A-III-ii-c : CHOEP MEDICAL ONCOLOGY 8640 8640 8640 8640 8640 8640 8640 8640
CM0953A-III-ii-d : Dose-adjusted EPOCH(etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) MEDICAL ONCOLOGY 6892 6892 6892 6892 6892 6892 6892 6892
CM0953A-III-ii-e : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A-III-iii : DIFFUSE LARGE B CELL LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-III-iii-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
CM0953A-III-iii-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) MEDICAL ONCOLOGY 46780 46780 46780 46780 46780 46780 46780 46780
CM0953A-III-iii-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) MEDICAL ONCOLOGY 42847 42847 42847 42847 42847 42847 42847 42847
CM0953A-III-iii-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) MEDICAL ONCOLOGY 32972 32972 32972 32972 32972 32972 32972 32972
CM0953A-III-iii-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) MEDICAL ONCOLOGY 32572 32572 32572 32572 32572 32572 32572 32572
CM0953A-III-iii-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) MEDICAL ONCOLOGY 59429 59429 59429 59429 59429 59429 59429 59429
CM0953A-III-iii-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) MEDICAL ONCOLOGY 61880 61880 61880 61880 61880 61880 61880 61880
CM0953A-III-iii-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) MEDICAL ONCOLOGY 10969 10969 10969 10969 10969 10969 10969 10969
CM0953A-III-iii-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) MEDICAL ONCOLOGY 12920 12920 12920 12920 12920 12920 12920 12920
CM0953A-III-iii-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) Rituximab MEDICAL ONCOLOGY 26818 26818 26818 26818 26818 26818 26818 26818
CM0953A-III-iii-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) MEDICAL ONCOLOGY 2818 2818 2818 2818 2818 2818 2818 2818
CM0953A-III-iii-f : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A-III-iv : AIDS-Related B-Cell Lymphomas MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-III-iv-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
CM0953A-III-iv-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) MEDICAL ONCOLOGY 46780 46780 46780 46780 46780 46780 46780 46780
CM0953A-III-iv-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) MEDICAL ONCOLOGY 42847 42847 42847 42847 42847 42847 42847 42847
CM0953A-III-iv-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) MEDICAL ONCOLOGY 32972 32972 32972 32972 32972 32972 32972 32972
CM0953A-III-iv-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) MEDICAL ONCOLOGY 32572 32572 32572 32572 32572 32572 32572 32572
CM0953A-III-iv-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) MEDICAL ONCOLOGY 59429 59429 59429 59429 59429 59429 59429 59429
CM0953A-III-iv-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) MEDICAL ONCOLOGY 61880 61880 61880 61880 61880 61880 61880 61880
CM0953A-III-iv-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) MEDICAL ONCOLOGY 10969 10969 10969 10969 10969 10969 10969 10969
CM0953A-III-iv-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) MEDICAL ONCOLOGY 12920 12920 12920 12920 12920 12920 12920 12920
CM0953A-III-iv-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab MEDICAL ONCOLOGY 26818 26818 26818 26818 26818 26818 26818 26818
CM0953A-III-iv-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) MEDICAL ONCOLOGY 2818 2818 2818 2818 2818 2818 2818 2818
CM0953A-III-iv-f : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A-III-v : Primary Cutaneous Marginal Zone or Follicle Center Lymphoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-III-v-a-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab MEDICAL ONCOLOGY 26818 26818 26818 26818 26818 26818 26818 26818
CM0953A-III-v-a-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) MEDICAL ONCOLOGY 2818 2818 2818 2818 2818 2818 2818 2818
CM0953A-III-v-b : Rituximab MEDICAL ONCOLOGY 25500 25500 25500 25500 25500 25500 25500 25500
CM0953A-III-v-c : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A-III-vi : Follicular Lymphoma (Grade 1-2) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-III-vi-a-1 : Bendamustine with or without rituximab MEDICAL ONCOLOGY 36500 36500 36500 36500 36500 36500 36500 36500
CM0953A-III-vi-a-2 : Bendamustine (-) rituximab MEDICAL ONCOLOGY 12500 12500 12500 12500 12500 12500 12500 12500
CM0953A-III-vi-b-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab MEDICAL ONCOLOGY 26818 26818 26818 26818 26818 26818 26818 26818
CM0953A-III-vi-b-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) MEDICAL ONCOLOGY 2818 2818 2818 2818 2818 2818 2818 2818
CM0953A-III-vi-c : Cyclophosphamide + Vincristine + Prednisone + Rituximab (RCVP) MEDICAL ONCOLOGY 25768 25768 25768 25768 25768 25768 25768 25768
CM0953A-III-vi-d : Rituximab MEDICAL ONCOLOGY 25500 25500 25500 25500 25500 25500 25500 25500
CM0953A-III-vi-e : Lenalidomide + Rituximab MEDICAL ONCOLOGY 4940 4940 4940 4940 4940 4940 4940 4940
CM0953A-III-vi-f : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0953A-III-vii : Extranodal NK/T-Cell Lymphoma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0953A-III-vii-a : SMILE MEDICAL ONCOLOGY 27483 27483 27483 27483 27483 27483 27483 27483
CM0953A-III-vii-b : DeVIC +RT MEDICAL ONCOLOGY 9163 9163 9163 9163 9163 9163 9163 9163
CM0953A-III-vii-c : VIPID MEDICAL ONCOLOGY 6619 6619 6619 6619 6619 6619 6619 6619
CM0953A-III-vii-d : Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0954 : Myelodysplastic Syndromes Treatment Regimens MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0954-i : Symptomatic Anemia With del(5q) with or without Other Cytogenetic Abnormalities MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0954-i-a : Lenalidomide MEDICAL ONCOLOGY 2575 2575 2575 2575 2575 2575 2575 2575
CM0954-ii : Symptomatic Anemia Without del(5q) and Serum Erythropoietin =500mU/mL MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0954-ii-a-1 : rHu-Epo with or without G-CSF MEDICAL ONCOLOGY 26080 26080 26080 26080 26080 26080 26080 26080
CM0954-ii-a-2 : rHu-Epo (-) G-CSF MEDICAL ONCOLOGY 25750 25750 25750 25750 25750 25750 25750 25750
CM0954-ii-b-1 : Darbepoetin alfa with or without G-CSF MEDICAL ONCOLOGY 9330 9330 9330 9330 9330 9330 9330 9330
CM0954-ii-b-2 : Darbepoetin alfa (-) G-CSF MEDICAL ONCOLOGY 9000 9000 9000 9000 9000 9000 9000 9000
CM0954-iii : Symptomatic Anemia Without del(5q), Serum Erythropoietin >500mU/mL, Unlikely to Respond to IST MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0954-iii-a-1 : Decitabine (15mg/m2) MEDICAL ONCOLOGY 15500 15500 15500 15500 15500 15500 15500 15500
CM0954-iii-a-2 : Decitabine (20mg/m2) MEDICAL ONCOLOGY 16500 16500 16500 16500 16500 16500 16500 16500
CM0954-iii-b : Lenalidomide MEDICAL ONCOLOGY 2575 2575 2575 2575 2575 2575 2575 2575
CM0955 : Multiple Myeloma MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0955-a : Lenalidomide (28 days) + Dexamethasone MEDICAL ONCOLOGY 6817 6817 6817 6817 6817 6817 6817 6817
CM0955-b : Lenalidomide (21 days) + Dexamethasone MEDICAL ONCOLOGY 5004 5004 5004 5004 5004 5004 5004 5004
CM0955-c : Lenalidomide MEDICAL ONCOLOGY 2575 2575 2575 2575 2575 2575 2575 2575
CM0955-d : Bendamustine + Lenalidomide + Dexamethasone MEDICAL ONCOLOGY 13639 13639 13639 13639 13639 13639 13639 13639
CM0955-e : Bendamustine MEDICAL ONCOLOGY 22000 22000 22000 22000 22000 22000 22000 22000
CM0955-f : Cyclophosphamide + Lenalidomide + Dexamethasone MEDICAL ONCOLOGY 5136 5136 5136 5136 5136 5136 5136 5136
CM0955-g : Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP) MEDICAL ONCOLOGY 5764 5764 5764 5764 5764 5764 5764 5764
CM0955-h : Dexamethasone + Thalidomide + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (DT-PACE) MEDICAL ONCOLOGY 7724 7724 7724 7724 7724 7724 7724 7724
CM0955-i : High-dose Cyclophosphamide MEDICAL ONCOLOGY 5140 5140 5140 5140 5140 5140 5140 5140
CM0955-j : VAD / VAMP MEDICAL ONCOLOGY 6104 6104 6104 6104 6104 6104 6104 6104
CM0955-k : Melphalan MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
CM0955-l : Melphalan + Prednisolone MEDICAL ONCOLOGY 1137 1137 1137 1137 1137 1137 1137 1137
CM0955-m : Thalidomide + Dexamethasone MEDICAL ONCOLOGY 2376 2376 2376 2376 2376 2376 2376 2376
CM0955-n : Melphalan / Prednisolone/Thalidomide(MPT) MEDICAL ONCOLOGY 2257 2257 2257 2257 2257 2257 2257 2257
CM0956 : ALL LYMPHOMA SALVAGE CHEMO (Package 953 to be utilised) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0957 : CHILDHOOD B CELL LYMPHOMA VARIABLE REGIMEN (Package 953 to be utilised) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0100-N : BREAST CANCER - TAMOXIFEN MEDICAL ONCOLOGY 100 100 100 100 100 100 100 100
CM0100-O : BREAST CANCER - AROMATASE INHIBITORS MEDICAL ONCOLOGY 1000 1000 1000 1000 1000 1000 1000 1000
CM0100-P : BREAST CANCER - Zoledronic Acid for skeletal metastasis MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
CM0124-c : PROSTATE CANCER - Zoledronic Acid for skeletal metastasis MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
CM0955-O : Multiple Myeloma - Zoledronic Acid MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
CM0100-a-III : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 21 days for 4 cycles MEDICAL ONCOLOGY 7000 7000 7000 7000 7000 7000 7000 7000
CM0100-a-IV : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 80mg/m2) Repeat cycle - weekly for 12 cycles MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
CM0101-a-IV : BLADDER CANCER - Radiosensitizing - Cisplatinc + 5-FU ; Days 1, 2, 3, 15, 16, and 17: IV hydration at a rate of 500mL/hour; followed by 5-FU 400mg/m2 IV push; followed by cisplatin 15mg/m2 IV over 1 hour as induction and consolidation therapy MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
CM0101-a-V : BLADDER CANCER -Radiosensitizing - Cisplatin + paclitaxel ; Days 1, 8, and 15: Paclitaxel 50mg/m2 ; Day 1-3, 8-10, 15-17: Cisplatin 15mg/m2; followed by twice-daily radiotherapy for 8 days MEDICAL ONCOLOGY 18400 18400 18400 18400 18400 18400 18400 18400
CM0101-a-VI : BLADDER CANCER -Radiosensitizing - 5-FU + mitomycin32 ; Day 1 of radiotherapy: Mitomycin 12mg/m2 IV bolus, plus ; Week 1 (fractions 1-5) and Week 4 (fractions 16-20) of radiotherapy: 5-FU 500mg/m2 continuous IV infusion (10 days total) MEDICAL ONCOLOGY 15100 15100 15100 15100 15100 15100 15100 15100
CM0101-c : BLADDER CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
CM0103 : OESOPHAGEAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0103-v: ESOPHAGEAL CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
CM0105 : COLORECTAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0106 : OSTEOSARCOMA/ BONE TUMORS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0106-vi : Other bone tumors - Mesenchymal Chordosarcoma VIDE (vincristine + ifosfamide + doxorubicin + etoposide) ; Day 1: Vincristine 1.4mg/m2 (max 2mg), ; Days 1-3: Doxorubicin 20mg/m2 IV + ifosfamide 3mg/m2 IV + mesna 3g/m2 + etoposide 150mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. MEDICAL ONCOLOGY 9200 9200 9200 9200 9200 9200 9200 9200
CM0110 : Neuroblastoma ALL STAGES MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM0114-i-b-1 : EWINGS SARCOMA - Induction Treatment - VAC/IE - VAC ; Day 1: Vincristine 2mg/m2 (max 2mg) IV, doxorubicin 75mg/m2 IV bolus, cyclophosphamide 1,200mg/m2 IV, mesna. ; Dactinomycin 1.25mg/m2 IV can be substituted for doxorubicin when a total doxorubicin dose of 375mg/m2 is reached. MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
CM0114-i-b-2 : EWINGS SARCOMA - Induction Treatment - VAC/IE - IE ; IE cycles ; Days 1-5: Ifosfamide 1,800mg/m2 IV + mesna + etoposide 100mg/m2 IV. ; Repeat each cycle every 3 weeks for 17 cycles. MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
CM0114-i-e : EWINGS SARCOMA - Induction Treatment - VACA ; Day 1: Vincristine 1.5mg/m2 IV + cyclophosphamide 1,200mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 10 cycles. MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
CM0117-e : VULVAL CANCER - Cisplatin + 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV MEDICAL ONCOLOGY 11100 11100 11100 11100 11100 11100 11100 11100
CM0128-ii-c-1 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
CM0128-ii-c-2 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - adjuvant temozolomide - preceeded by Concurrent Temozolomide (with RT) ; Temozolomide 150-200mg/m2/day for 5 days. ; Repeat cycle every 28 days for 6 cycles MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
CM0130 I a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily MEDICAL ONCOLOGY 19250 19250 19250 19250 19250 19250 19250 19250
CM0130 I b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. MEDICAL ONCOLOGY 29250 29250 29250 29250 29250 29250 29250 29250
CM0130 I c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Bevacizumab + IFN-alpha ; Bevacizumab 10mg/kg IV every 2 weeks + IFN-alpha. MEDICAL ONCOLOGY 66750 66750 66750 66750 66750 66750 66750 66750
CM0130 I d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily MEDICAL ONCOLOGY 3650 3650 3650 3650 3650 3650 3650 3650
CM0130 II a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Everolimus ; Everolimus 10mg orally once daily MEDICAL ONCOLOGY 37250 37250 37250 37250 37250 37250 37250 37250
CM0130 II b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Pazopanib ; Pazopanib 800mg orally once daily MEDICAL ONCOLOGY 19250 19250 19250 19250 19250 19250 19250 19250
CM0130 II c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sorafenib ; Sorafenib 400mg orally twice daily MEDICAL ONCOLOGY 3650 3650 3650 3650 3650 3650 3650 3650
CM0130 II d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. MEDICAL ONCOLOGY 29250 29250 29250 29250 29250 29250 29250 29250
CM0130 II e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. MEDICAL ONCOLOGY 66250 66250 66250 66250 66250 66250 66250 66250
CM0130 III a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. MEDICAL ONCOLOGY 29250 29250 29250 29250 29250 29250 29250 29250
CM0130 III b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. MEDICAL ONCOLOGY 66250 66250 66250 66250 66250 66250 66250 66250
CM0130 III c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Everolimus ; Everolimus 10mg orally once daily MEDICAL ONCOLOGY 37250 37250 37250 37250 37250 37250 37250 37250
CM0130 III d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Erlotinib ; Erlotinib 150mg orally once daily MEDICAL ONCOLOGY 3400 3400 3400 3400 3400 3400 3400 3400
CM0130 III e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily MEDICAL ONCOLOGY 19250 19250 19250 19250 19250 19250 19250 19250
CM0130 III f : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily MEDICAL ONCOLOGY 3650 3650 3650 3650 3650 3650 3650 3650
CM0130 IV: RENAL CELL CARCINOMARENAL CELL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0131-i-g : UNKNOWN PRIMARY - Adenocarcinoma - mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
CM0131-i-h : UNKNOWN PRIMARY - Adenocarcinoma - CapeOX ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Day 1-14: Capecitabine 850-1000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 16 cycles. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
CM0131-i-i : UNKNOWN PRIMARY - Adenocarcinoma - Irinotecan + carboplatin ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for up to 6 cycles MEDICAL ONCOLOGY 7700 7700 7700 7700 7700 7700 7700 7700
CM0131-ii-c : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + carboplatin ; Day 1: Carboplatin AUC 6mg per min/mL IV over 30 minutes + paclitaxel 200mg/m2 IV over 3 hours. ; Repeat cycle every 3 weeks for 8 cycles in responding patients and for 6 cycles maximum in patients with stable disease MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
CM0131-ii-d : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + gemcitabine ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. MEDICAL ONCOLOGY 5250 5250 5250 5250 5250 5250 5250 5250
CM0131-ii-e : UNKNOWN PRIMARY - Squamous cell carcinoma -mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles. MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
CM0131-ii-f : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + cisplatin ; Day 1: Paclitaxel 175mg/m2 IV + cisplatin 60mg/m2 IV. ; Repeat cycle every 3 weeks. MEDICAL ONCOLOGY 6450 6450 6450 6450 6450 6450 6450 6450
CM0131-ii-g : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + carboplatin ; Day 1: Docetaxel 75mg/m2 IV over 30 minutes + carboplatin AUC 5mg per min/mL IV over 30 minutes. ; Repeat cycle every 3 weeks for 8 cycles MEDICAL ONCOLOGY 8700 8700 8700 8700 8700 8700 8700 8700
CM0131-ii-h : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 60mg/m2 IV + cisplatin 80mg/m2 IV. ; Repeat cycle every 3 weeks for 2 cycles and an additional 4 cycles until disease progression is demonstrated MEDICAL ONCOLOGY 5040 5040 5040 5040 5040 5040 5040 5040
CM0131-ii-i : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. MEDICAL ONCOLOGY 3820 3820 3820 3820 3820 3820 3820 3820
CM0131-ii-j : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + fluorouracil ; Days 1-5: Cisplatin 20mg/m2 IV ; Days 1-5: Fluorouracil 700mg/m2/day IV via continuous infusion over 24 hours. ; Repeat cycle every 4 weeks for 3 cycles. MEDICAL ONCOLOGY 7050 7050 7050 7050 7050 7050 7050 7050
CM0952A-I-iii-j : Chronic Myeloid Leukemia (CML) - Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM0952A-II-z : Acute Myeloid Leukemia (AML) - Other Regimen MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
CM1419 : Acute lymphoblastic leukemia: Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1420 : Acute myeloid leukemia: Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1421 : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1422 : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1423 : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1424 : Retinoblastoma (Intraocular): supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1425 : Retinoblastoma (extraocular): supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1426 : Brain tumors: supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1427 : Histiocytosis: supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1428 : Bone tumors/soft tissue sarcomas : supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1429 : Chronic Myeloid Leukemia : supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1430 : Terminally IllPalliative And Supportive Therapy - Per month MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 20000 20000 20000 20000 20000 20000 20000 20000
CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage MEDICAL ONCOLOGY 30000 30000 30000 30000 30000 30000 30000 30000
CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 15000 15000 15000 15000 15000 15000 15000 15000
CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 25000 25000 25000 25000 25000 25000 25000 25000
CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 50000 50000 50000 50000 50000 50000 50000 50000
CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 20000 20000 20000 20000 20000 20000 20000 20000
CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000

Say hello to us , Toll-Free

1800 425 3993

Write to us

[email protected]
[email protected]

Reach us At

The Project Director

Tamil Nadu Health Systems Project (TNHSP)
3rd Floor, DMS Annex New Building
259 Anna Salai, Teynampet
Chennai - 600 006, Tamil Nadu.

CMCHIS Project Office

Chief Minister's Comprehensive Health Insurance Scheme
No.226,Om Sakthi Towers,
Kilpauk Garden Road, Kilpauk,
Chennai-600010, Tamil Nadu

Visitors Count : 2195 / 2567652